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Abstract 
 
Introduction: Neurons are found dying in postmortem brain tissues of patients with 
neurodegenerative conditions. The cause of the neuronal death is currently unknown 
and thus, no effective treatment is available to stop/cure the diseases. Therefore, 
further insights into the cellular and molecular mechanisms, especially those that 
may be common across neurodegenerative diseases, would help to inform the 
development of effective means to prevent and to efficiently treat them. 
Mitochondrial dysfunction, protein aggregation and altered calcium signalling have 
been found across neurodegenerative diseases. Based on this observation, a treatment 
with the mitochondrial complex I inhibitor rotenone was first carried out in mice 
cortical neurons to investigate the temporal molecular events contributing to 
neuronal death after treatment. In addition, a cross-disease models study was also 
conducted to help advance the understanding and highlight the common cellular and 
molecular biological defects caused by dysfunctional ubiquitin-proteasome system 
(UPS) for protein aggregation and treatment of N-methyl-D-aspartate (NMDA) for 
altering intracellular calcium. As a result, sulfiredoxin (Srxn1) an antioxidant that 
regulates both H2O2 and nitric oxide (NO) signaling was identified as a potential 
neuroprotective agent and its protective effect was demonstrated in rotenone-treated 
neurons. 
Methods: Microarray analysis was performed using cultured neocortical neurons 
treated with 10 nM rotenone for 8, 15, and 24 h. Genes showing at least ± 1.2-fold 
change in expression at one time point were considered significant. For cross-models 
analysis, previously published expression profiles of 200 μM NMDA (5, 15 and 24 h) 
and 1 μM lactacystin (4.5, 7.5, 24 and 48 h)-treated cortical neurons were compared 
with the expression profile of rotenone. Genes showing at least ± 1.5-fold change in 
expression at one time point were considered significant. To demonstrate the 
neuroprotective role of Srxn1, an inducible Srxn1 expression system in SH-SY5Y 
was established. This stably transfected SH-SY5Y was differentiated and treated 
with low level of rotenone (0.1 μM) for 7 days to mimic the chronic condition of 
neurodegenerative diseases. The protective effect was assessed by cell viability assay, 
western blot and microscopy. 
Results: Transcriptomic analysis of rotenone-treated cortical neurons revealed major 
changes to nine biological processes, including those eliciting mitochondrial 
dysfunction, activation of calcium signaling, increased expression of apoptotic genes, 
and downplay of chaperones/co-chaperones, ubiquitin-proteasome system and 
autophagy. By comparing the transcriptomic profile of rotenone with the 
transcriptomic profiles of lactacystin and NMDA, further revealed the importance of 
oxidative stress, calcium signaling and autophagy inhibition. Overexpression of 
Srxn1 significantly increases cell viability and prevents α-fodrin degradation in 
rotenone treatment. Furthermore, cells that overexpressing Srxn1 maintain healthy 
neurite network.  
Conclusion: These data reveal that Srxn1 protects neuronal injury caused by 
mitochondrial dysfunction. It is anticipated that Srxn1 rescued neurons by re-
activating 2-Cys peroxiredoxins (Prxs) peroxide reductase activity, maintaining 
cellular Prxs level, inhibiting oxidative inactivation of the autophagic machinery and 
preserving neurite integrity.  
Implications: Common molecular and cellular mechanisms identified from the 
multiple-models-comparing approach could be very valuable for the development of 
therapeutics for a more common disease with a larger potential market. Srxn1 is a 
critical antioxidant protein that can be used as molecular target to develop 
therapeutics for patients with neurodegenerative disease.  
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1.1 Introduction: What is neurodegenerative disease? 
Neurodegenerative disease is a term used to describe a range of conditions affecting 
neurons in the human brain.  Neurodegenerative diseases such as Alzheimer’s 
disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and 
Huntington’s disease (HD) are incurable and debilitating conditions occurring over 
many years or even decades that result in progressive degeneration and / or death of 
nerve cells.   
Due to the chronic and incurable nature of these conditions, the economic 
burden of neurodegenerative diseases is correspondingly large. The 2016 World 
Alzheimer Report estimated that there are 47 million people live with dementia 
worldwide with an estimated cost of US $818 billion, and this will grow to more than 
131 million people by 2050 and will consume a trillion dollars by 2018 (Prince et al., 
2016). In addition, PD Foundation estimated that more than 10 million people 
worldwide are living with PD and the combined cost for treatment, social security 
payments and lost income from inability to work, is estimated to be nearly $25 
billion per year in the United States alone (PD foundation, 2017). As for HD, it is 
estimated that about 5 to 7 per 100,000 people in western countries have HD 
(Huntington’s New South Wales, 2017). Therefore, the total number of people with 
neurodegenerative diseases is enormous and the economic burden of these diseases is 
significant.  
Hence, the study of the basic neuronal cell death mechanisms involved in 
these diseases and an understanding of how the brain responds to death stimuli are of 
utmost importance. The answers to these fundamental questions will form the 
foundation for new treatments for these diseases.  
 
 
1.2 Mechanism of neuronal cell death – programmed cell death 
There are a number of recognized ways in which neuronal cells can die during 
neurodegenerative diseases, including apoptosis, autophagy and necrosis. All these 
cell death mechanisms can be genetically ‘programmed’ by the cells in response to 
excessive damage, or unfavorable intracellular or extracellular conditions. Thus, it is 
termed programmed cell death (PCD). PCD is an active process that requires ATP, 
changes in gene expression and protein synthesis.  
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There are a few types of PCD identified so far (for instance apoptosis, 
autophagic cell death and necroptosis) and more than one type of cell death has been 
observed to coexist in the same postmortem tissues (Perier et al., 2012). In addition, 
there are overlaps in some of the biochemical and morphological features between 
the different types of cell death (Venderova and Park, 2012). However, only 
apoptosis and autophagy will be reviewed here.  
 
1.2.1 Apoptosis  
Typical morphological features of apoptotic cells include shrinking of the cell, 
membrane blebbing, compartmentalization, chromatin condensation, and DNA 
fragmentation. The cell membrane of apoptotic cells remains intact and it expresses 
cell surface markers that target it for recognition and phagocytosis (Gorman, 2008). 
There are two major ways to trigger the onset of apoptosis in response to 
death stimuli: extrinsic and intrinsic pathways (Figure 1.1). In the extrinsic pathway, 
death receptors from the tumor necrosis factor receptor (TNFR) family (Fas, DR3, 
DR6, and TRAIL receptors) are trimerized after the binding of death ligands. The 
death domains found in the intracellular domain of the death receptors then bind pro-
caspase-8 (or pro-caspase-10) forming a death-inducing signaling complex. The 
proximity-induced autoactivation of caspase-8 or caspase-10 leads to their cleavage 
and full activation (Gorman, 2008; Schulze-Osthoff et al., 1998). Effector caspases 
(e.g. caspase-3 and caspase-7) are activated to cleave a wide variety of protein 
substrates to cause the degradation and demise of the cell (Stroh and Schulze-Osthoff, 
1998). 
On the other hand, the intrinsic (mitochondrial) pathway is activated by 
cellular stressors, such as DNA damage, reactive oxygen species (ROS), or loss of 
trophic support. The central phenomenon in this pathway is the mitochondrial outer 
membrane permeabilization (MOMP), which results in the release of mitochondrial 
intermembrane space molecules into the cytosol. The integrity of the mitochondrial 
outer membrane is tightly regulated by the BCL-2 family of proteins (Cory and 
Adams, 2002). They are divided into three subfamilies based on the number of Bcl-2 
homolog (BH) domains that they possessed. Members with the BH4 domain (Bcl-2, 
BCL-xL, BCL-W, MCL-1, and others) form the antiapoptotic subfamily and they 
prevent MOMP. Members lacking the BH4 domain (BAX, BAK and BOK) or solely 
with BH3 (BH3-only) (BID, BAD, BIM, BLK, PUMA, NOXA, and BNIP3L) form 
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the proapoptotic subfamilies and cause MOMP. When activated, BAX, BAK and 
BOK can translocate to the mitochondrial membrane and form holes by 
oligomerization. This oligomerization can be inhibited by Bcl-2, which in turn can be 
sequestered by BH3-only proteins. BAD can heterodimerize with BCL-xL or BCL-2, 
which neutralizes their protective effect and promotes cell death (Yang et al. 1995). 
BID, BIM, and PUMA can trigger oligomerization of BAX or BAK and participate 
in MOMP.  
Once there is MOMP, a number of molecules can freely diffuse from the 
mitochondria, including cytochrome c (Cyt c), Smac/DIABLO (Du et al. 2000; 
Green and Reed 1998; Verhagen et al. 2000), Omi/HtrA2, apoptosis-inducing factor 
(AIF) and endonuclease G (EndoG). Cyt c induces polymerization of cytosolic Apaf-
1, which is an adaptor protein of the mitochondrial pathway and is required for 
activation of caspase-9. Cyt c–Apaf-1 complex then binds procaspase-9 via a 
homologous death fold called CARD domain (Zou et al., 1999). In the next step, 
caspase-9 becomes activated and Apaf-1 and caspase-9 form the apoptosome 
complex (Li et al., 1997). This apoptosome complex then plays a role in activation of 
caspase-3 (Zou et al., 1997).  
It has also been reported that cell death also occurs after MOMP even in the 
absence of caspase activity (for example in Apaf-1- and caspase 9-deficient 
backgrounds), but in a much slower kinetic (Tait and Green, 2010). This intrinsic 
caspase-independent pathway can be triggered either by the release of AIF and 
EndoG, which translocate to nucleus to cause chromatin condensation, DNA 
fragmentation and DNA loss (Guiney et al., 2017; Yang et al., 2017) or through a 
progressive loss of mitochondrial function such as ATP synthesis after MOMP.  
Studies of post-mortem brain tissue indicate that neuronal apoptosis occurs in 
AD (Colurso et al., 2003; Smale et al., 1995). Neurons treated with β-amyloid exhibit 
morphological and biochemical characteristics of apoptosis, including membrane 
blebbing, compaction of nuclear chromatin, and internucleosomal DNA 
fragmentation (Loo et al., 1993) and the presence of active caspases (Forloni et al., 
1996). The presence of apoptotic chromatin clumps along with TUNEL staining in 
neuromelanin-containing cells in the substantia nigra of PD post-mortem tissue 
suggests that apoptotic cell death contributes to neuronal loss in PD (Lev et al., 2003; 
Tatton et al., 1998; Tompkins et al., 1997). Activated caspase-3 has also been 
observed in these cells (Tatton, 2000). There is also evidence for a role of the 
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extrinsic apoptotic pathway in post-mortem studies of PD brain as shown by the 
increased levels of TNFα, soluble Fas and the Fas adaptor protein FADD in the 
midbrain of PD patients (Hartmann et al., 2002; Mogi et al., 1994, 1996). Similarly, 
there is substantial evidence showing that neuronal death in ALS and HD is also via 
apoptosis (Dragunow et al., 1995; Portera-Cailliau et al., 1995; Sathasivam et al., 
2001). 
 
Figure 1.1: A summary of the pathways that lead to apoptosis.  
 
 
1.2.2 Autophagic cell death 
Autophagic cell death is a type of cell death that is caused by the inhibition of 
autophagy (Guiney et al., 2017). Autophagy is a recycling process by which cells 
disposes of their damaged organelles and long-lived proteins by sequestering them in 
an autophagic vacuole called the autophagosome and transporting them to the 
lysosome for enzymatic degradation. There are five major steps involved in 
autophagy: induction of autophagy, autophagosome formation, autophagosome 
docking, lysosomal fusion and autophagic breakdown (Figure 1.2).  
The induction of autophagy is the fusion of precursor vesicles facilitated by 
various autophagy (ATG) proteins. Mammalian core ATG proteins can be classified 
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into several functional units: (1) the ULK complex (a serine-threonine kinase 
complex consisted of ULK1, ULK2, ATG13, ATG101 and FIP200); (2) ATG9L 
(ATG9L1 and ATG9L2); (3) ATG14L complex (composed of ATG14L, VPS34, 
beclin-1 and VPS15); (4) the ATG2-WIPI complex (composed of WIPI family 
members, WIPI1-WIPI4, and ATG2); (5) the ATG16L1 complex (composed of 
ATG16L1, ATG5 and ATG12); (6) the LC3 conjugating system (Shibutani et al., 
2015).  
The ULK complex is the most upstream ATG players in the autophagy 
pathway. Its activity is negatively regulated by a serine/threonine kinase called 
mammalian target of rapamycin (mTOR). Once the autophagy is successfully 
initiated, ATG7 and ATG10 catalyze the formation ATG16L1 complex, which is a 
component of the phagophore. In addition, ATG9 is also found on the membrane of 
phagophore. When the phagophore is developing, the cleavage of microtubule-
associated protein 1 light chain 3 (LC3) by ATG4B to form LC3-I is essential. There 
are seven mammalian orthologs of LC3 (LC3A, LC3B, LC3C, GABARAP, 
GABARAPL1, GABARAPL2 and GABARAPL3) (Shibutani et al., 2015). The 
resulting LC3-I is then conjugated to phosphatidylethanolamine by ATG7 and ATG3 
to form LC3-II, which remains associated with the matured autophagosome. Once 
the autophagosomes are mature, they are transported along the microtubules to the 
lysosome-rich perinuclear region. In neurons, autophagosomes formed at the distal 
tip of axons are transported towards the cell body by dynein-mediated retrograde 
transport. The fusion of autophagosomes with lysosomes is mediated by VAMP7, 
VAMP8 and VTI1B. The degradation of autophagy substrates can only occur 
efficiently when the acidic lysosomal pH and the degrading enzymes such as 
cathepsins, lysozyme, glycosidase and esterase, are functioning correctly. Also, 
sufficient lysosomes must also be available. Transcription factor EB (TFEB) has 
been identified as a master regulator for lysosomal biogenesis. The malfunction of 
any part of the process can contribute to the impairment of autophagy-lysosomal 
pathway (ALP).  
The role for altered autophagy in neurodegenerative diseases come from the 
observation that a lot of autophagic vesicles (due to the blocking of lysosomal 
fusion/degradation) were accumulated in the affected neurons of AD (Boland et al., 
2008; Nixon et al., 2005). Additionally, several autophagy-related genes were found 
mutated in the disease. For example, gain-of-function mutations of LRRK2 gene 
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causes PD and LRRK2 has been demonstrated to negatively regulate autophagy 
(Alegre-Abarrategui et al., 2009; Manzoni et al., 2013).  
  
Figure 1.2: The autophagy pathway. Blue text highlights the steps involved in 
autophagy from the initiation of autophagy to the substrate degradation in lysosome. 
Labels in green boxes indicate core ATG proteins required for autophagosome 
formation. Red text highlights points of compromise in the pathway that have been 
demonstrated in neurodegenerative disease. (Figure modified from Frake et al., 2015) 
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1.3 Oxidative stress and mitochondrial dysfunction as the common themes in 
neurodegenerative diseases 
Even though each neurodegenerative disease has different causes, genetic mutations 
and patterns of neuronal death, they display a number of common features that 
include oxidative stress and mitochondrial dysfunction.  
 Oxidative stress is considered as a major contributing factor in the 
pathogenesis of neurodegenerative diseases as the levels of total oxidized lipids, 
proteins and DNA were found highly increased in diseased brains (Butterfield et al., 
2010; Toulorge et al., 2016). At the same time, antioxidant proteins levels and 
activities were also deregulated. Antioxidants in the form of flavonoids and phenolic 
compounds have been shown to be effective in prevention/treatment of 
neurodegeneration (Lalkovicova and Danielisova, 2016; Molino et al., 2016) 
As mitochondria is the endogeneous source of ROS, mitochondrial 
dysfunction is believed to be the cause of oxidative stress during pathological 
conditions. Several reports have demonstrated that mitochondrial involvement is 
likely to be an important common theme in these diseases as mitochondria have 
recently been found to interact with many specific proteins implicated in genetic 
forms of neurodegenerative diseases (Table 1.1).  
Mitochondria are double membrane organelles supplying cells with energy 
through production of ATP. ATP production is performed by the oxidative 
phosphorylation system (OXPHOS). This system is consisted of five large multi-
subunit complexes and is embedded in the inner mitochondrial membrane (IMM). 
Mitochondria are also involved in intracellular calcium regulation and act as 
transducers of intracellular signalling pathways for PCD (Fannjiang et al., 2004; 
Nagley et al., 2010; Young et al., 2008). Furthermore, mitochondria are also the main 
site of reactive oxygen species (ROS) generation within the cell (Lenaz et al., 2002) 
which are natural byproducts of OXPHOS. Numerous cellular processes in neurons 
such as synaptic transmission, cellular remodelling and cell death are tightly 
associated with mitochondrial function (Nagley et al., 2010; von Bernhardi and 
Eugenin, 2012). Dysfunction of complex I is the most frequently encountered among 
the so called “primary” defects of mitochondrial energy metabolism (Smeitink et al., 
2001). The involvement of complex I in many diseases can be due to the following 
(Smeitink et al., 2004): 1) it is the largest among the respiratory chain complexes 
with 46 subunits; 2) the NADH-ubiquinone oxidoreductase activity of the complex  
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Table 1.1: A summary of a role for mitochondrial dysfunction in the pathogenesis of 
multiple neurodegenerative disorders and in animal models of these diseases. 
Disease Key proteins 
implicated 
Association with mitochondria 
Alzheimer’s 
disease 
Amyloid beta 
precursor protein 
Localized on mitochondrial membrane (Spuch 
et al., 2012) 
 Presenilin 1 and 
Presenilin 2 
Localized on mitochondrial associated 
membrane a specialized subcompartment of the 
endoplasmic reticulum (ER) that connects ER 
to mitochondria (Schon and Area-Gomez, 
2010) 
Parkinson’s 
disease 
α-synuclein Constitutively present in brain mitochondria 
(Devi and Anandatheerthavarada, 2010) 
 Parkin An E3-ubiquitin-ligase that translocates to the 
mitochondria when the organelles are 
depolarized (Hauser and Hastings, 2013) 
 DJ-1 Mitochondrial level of DJ-1 is increased during 
oxidative stress (Joselin et al., 2012) 
 PTEN Induced 
Putative Kinase 1 
A kinase localized to mitochondria (Chen and 
Dorn, 2013). 
 leucine-rich 
repeat kinase 2 
Found to interact with mitochondrial fission 
protein Dynamin like protein 1 (Niu et al., 
2012; Wang et al., 2012) 
 HtrA serine 
peptidase 2 
Located in the mitochondrial intermembrane 
space (Li et al., 2002).  
Amyotrophic 
lateral sclerosis 
Superoxide 
dismutase 1 
The mutated protein is preferentially associated 
with mitochondria and causes mitochondrial 
impairment (Shi et al., 2010).  
Huntington’s 
disease 
Huntingtin Mutant huntingtin protein associated with brain 
mitochondria (Oliveira, 2010) 
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contributes to 40% of the mitochondrial proton-motive force, utilized for ATP 
synthesis and transport processes; 3) it is a major contributor to ROS production in 
the cell. Therefore, the study of cell death mechanisms induced by mitochondrial 
dysfunction due to complex I inhibition will be the key for the understanding of 
neurodegenerative diseases pathogenesis. 
 
1.4 Induction of mitochondrial dysfunction using rotenone 
1.4.1 What is rotenone? 
Rotenone is an odorless chemical used as a broad-spectrum insecticide, piscicide 
(fish killer), and pesticide. It occurs naturally in the seeds and stems of several plants, 
such as the jicama vine plant. It is extremely hydrophobic and crosses biologic 
membranes easily and independently of transporters. Rotenone acts directly on two 
targets in the cell: (1) It binds specifically to mitochondrial complex I (Sherer et al., 
2003), inhibiting the flow of electrons through the respiratory chain. This specific 
interaction of rotenone with complex I was demonstrated by replacing the 
endogenous subunit in human neuroblastoma cells with the single-subunit NADH 
dehydrogenase from Saccharomyces cerevisiae. The substitution of this rotenone-
insensitive complex I attenuated rotenone’s toxic effects. (2) Rotenone 
depolymerizes microtubules (Marshall and Himes, 1978). The former activity does 
not explain the selectivity of rotenone toxicity on dopaminergic neurons as it impacts 
complex I in all cells of the brain (Betarbet et al., 2000) while the microtubule-
depolymerizing activity of rotenone is critical in determining its selective toxicity 
(Feng, 2006; Ren et al., 2005).  
 
1.4.2 Mechanism of rotenone action 
Due to the multiple roles of mitochondria, the consequences of inhibition of 
mitochondrial complex I by rotenone are multifarious (Figure 1.3). As an inhibitor of 
mitochondrial respiration, rotenone exerts toxicity by reducing ATP production and 
leads to bioenergetic crisis. Generation of ROS, which drives further oxidative stress, 
is thought to be a result of the accumulation of electrons that occurs upon complex I 
inhibition, and indeed, rotenone-induced toxicity secondary to oxidative stress has  
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Figure 1.3: A summary of the reported mechanism of rotenone action. Rotenone-
mediated cell death via complex I inhibition-dependent and -independent pathway. 
Complex I-independent pathway is less understood, in that rotenone disrupts 
microtubule stabilization and leads to aberrant autophagy. On the other hand, by 
inhibiting complex I, rotenone dampens ATP production and triggers oxidative stress. 
By reducing ATP synthesis, rotenone inhibits many ATP-dependent cellular 
processes such as glutathione (GSH) synthesis, ubiquitin-proteasome system (UPS) 
and autophagy. During oxidative stress triggered by rotenone, activation of transient 
receptor potential cation (TRPM2) channel and phosphorylation of NMDA receptors 
causes  an increase of cytosolic free calcium and leading to calpain activation 
(caspase-independent cell death). The simultaneous involvement of caspase-
dependent cell death was also triggers by oxidative stress, causing downstream 
inhibition of autophagy. In addition, complex I inhibition also induces the 
extracellular release of glutamate.   
 
 
 
 
 
COMPLEX I 
INHIBITION-
INDEPENDENT 
PATHWAY 
COMPLEX I INHIBITION-
DEPENDENT PATHWAY 
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been extensively studied and is attenuated by antioxidants in vitro (Higgins et al., 
2010). Additionally, inhibition of complex I may lead to aberrant opening of the 
mitochondrial permeability transition pore, which can cause depolarization of 
mitochondria, and facilitate mitochondrial-mediated programmed or necrotic cell 
death (Nagley et al., 2010). In fact, nanomolar concentrations of rotenone have been 
shown to selectively cause caspase-3 activation in dopaminergic neurons and the 
caspase-3 inhibitor DEVD-fmk can attenuate rotenone-induced death of 
dopaminergic neurons in vitro (Ahmadi et al., 2003). Likewise, overexpression of 
Bcl-2, a mitochondria-resident anti-apoptotic protein that regulates the permeability 
of the outer mitochondrial membrane (OMM) (Chipuk and Green, 2008), was shown 
to dramatically inhibit rotenone-induced changes in mitochondrial potential, further 
confirming involvement of mitochondrial dysfunction in rotenone-induced PCD 
(Tada-Oikawa et al., 2003). Rotenone can elicit caspase-independent PCD (Lim et al., 
2007) consistent with recent evidence of the parallel recruitment of different death 
signalling pathways (Nagley et al., 2010). Moreover, low nanomolar concentrations 
of rotenone have been shown to significantly increase NMDA receptor-mediated 
Ca2+ influx (Wu and Johnson, 2007, 2009). Thus, the mechanisms of ATP depletion, 
Ca2+ overload and oxidative stress may converge as a result of rotenone-induced 
inhibition of complex I. 
On the other hand, the complex I inhibition-independent mechanism of 
rotenone currently is not well-understood. Studies have shown that rotenone disrupts 
microtubule stabilization by binding to the colchicine site on tubulin heterodimers 
(Marshall and Himes, 1978; Ren et al., 2005). A recent study also demonstrated that 
rotenone induces microtubule destabilization by activating glycogen synthase kinase-
3β (GSK3β), which in turns phosphorylates tau, a microtubule-associated protein, 
and reduces its binding to microtubules (Hongo et al., 2012). Disrupting microtubule 
stabilization causes the accumulation of neurotransmitter-containing vesicles in the 
soma and increased cytosolic concentration of the neurotransmitter leaked from the 
vesicles (Ren et al., 2005). In the case of dopaminergic neurons, elevated cytosolic 
concentration of dopamine causes greater oxidative stress because of dopamine 
oxidation (Ren et al., 2005). However, neurons that do not contain an oxidizable 
neurotransmitter (e.g. GABAergic or glutamatergic neurons) are spared even though 
their microtubules are depolymerized to a similar extent (Feng, 2006). Therefore, this 
explains the selective vulnerability of midbrain dopaminergic neurons in PD.  
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1.5 Protein cysteine oxidation in neurodegenerative diseases 
The substrate specificity and biomolecular alterations caused by ROS is the key to 
understand the exact regulatory role of oxidative stress in the signal transduction 
events leading to neuronal death. An important cellular target or sensor of ROS is the 
thiol group of the amino acid cysteine (Cys) (Garcia-Garcia et al., 2012). Redox-
sensitive Cys can undergo a number of reversible and irreversible thiol modifications 
during oxidative stress (Figure 1.4). By regulating protein structure and activity, thiol 
modifications can regulate a variety of physiological processes. 
 
 
Figure 1.4: Types of oxidative Cys modifications. (Taken from Murray and Van Eyk, 
2012) 
  
To protect thiol groups from oxidation and to repair those that may have 
become oxidised as a result of normal or aberrant cellular metabolism, the cells 
possess thiol redox buffering systems such as the GSH system (GSH/glutathione 
disulphide (GSSG)/glutathione-S-transferases (GST) (Townsend, 2007)), thioredoxin 
system (thioredoxin (Trx), thioredoxin reductase and NADPH), protein disulphide 
isomerases, peroxiredoxins (Prx) and the thiol disulphide oxidoreductases that 
include thioredoxin (Trx), glutaredoxins (Grx). 
 There are several lines of evidence to demonstrate thiol-redox disturbance in 
neurodegeneration. Increased S-nitrosylation (SNO) of proteins has been described 
in human diseased brains and animal disease model (Fang et al., 2007; Gu and 
Robinson, 2016; Nakamura et al., 2015). Likewise, increase S-glutathionylation 
(SSG) of transient receptor potential cation channel 5 (TRPC5) has been reported to 
contribute to the loss of striatal neurons in HD (Hong et al., 2015). Increased S-
glutathionylated proteins have also been observed in AD brain with a proteomics 
approach (Newman et al., 2007). And deficiency in the thiol buffering system such 
as Grx (Johnson et al., 2015) exacerbates neurodegeneration. 
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1.6 The role of sulfiredoxin (Srxn1) in thiol-redox homoestasis  
1.6.1 The role of Srxn1 
Initially, the oxidation of Cys by H2O2 from sulfenic acid (-SOH) to sulfinic acid 
(-SO2H) was thought to be irreversible (Jacob et al., 2004), however, the belief was 
overturned with the discovery of Srxn1 as the Cys sulfinic acid reductase (Biteau et 
al., 2003). To date, Srxn1 has been found to have multiple roles in thiol-redox 
homeostasis by being a: 1) a cys sulfinic acid reductase; 2) a deglutathionylating 
enzyme; and 3) a denitrosylase.   
 
1.6.1.1 Srxn1, a cysteine sulfinic acid reductase specific to 2-cys peroxiredoxins 
The critical Cys residues of many proteins, including peroxiredoxins (Prxs), α1-
antitrypsin (Griffiths et al., 2002), carbonic anhydrase III (Mallis et al., 2002), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Souza and Radi, 1998), 
protein-tyrosine phosphatase 1B (PTP1B, Wang et al., 2004b), and 
metalloproteinases (Fu et al., 2001), are oxidized to sulfinic acid. Indeed, 1.4% of the 
Cys residues of soluble proteins in rat liver were detected as sulfinic acid (Woo et al., 
2005). Reversible oxidation of Cys to disulfide or sulfenic acid, both of which are 
readily reduced by thiols such as GSH and Trx while reversible oxidation of sulfinic 
acid to sulfenic acid is catalyzed by two ATP-dependent reductases designated Srxn1 
and sestrin (Woo et al., 2005). However, Srxn1 only binds to and reduces the Cys 
sulfinic acid of Prx enzymes in vitro (Woo et al., 2005) and sulfinic acid Prxs can 
only be reactivated by Srxn1 but not sestrin (Woo et al., 2009). Because of its 
specificity to Prxs, this suggested that Srxn1 is involved in H2O2-mediated signalling.  
Prxs are a family of peroxidases that are highly expressed (around 0.1-0.8% 
of the soluble protein) in human cells (Chae et al., 1999). They function as a first 
defence mechanism is to reduce H2O2, alkylhydroperoxide (ROOH), or peroxynitrite 
(ONOO-). Mammalian Prxs exist in six isoforms, which can be divided into three 
subgroups namely, 2-Cys (Prx I-IV), atypical 2-Cys (Prx V), and 1-Cys (Prx VI) 
subgroups (Rhee et al., 2001). Among Prxs, the 2-Cys subgroup (Prx I-IV) are the 
only substrate for Srxn1 enzyme activity (Woo et al., 2005). Prxs show distinct 
subcellular distributions: Prx I and Prx II are present in the cytosol, Prx IV is 
localized to the ER, and Prx III is synthesized with a mitochondrial targeting 
sequence and becomes restricted to mitochondria (Kil et al., 2015). Srxn1 is 
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predominantly cytosolic so it can repair Prx I and Prx II. Srxn1 can also be imported 
into mitochondria to rescue hyperoxidized Prx III (Kil et al., 201; Noh et al., 2009). 
 
1.6.1.2 Srxn1 as a deglutathionylating enzyme 
Glutathionylation is a post-translational modification that occurs during oxidative 
and nitrosative stress in which a mixed disulfide between Cys residues in proteins 
and GSH is formed (Findlay et al., 2005). Glutathionylation is thought to be 
protective as the glutathionylated proteins might be (1) protected from irreversible 
oxidative modifications, the end result of which is degradation, and (2) involved in 
redox-mediated cell signalling (Findlay et al., 2006). There are a number of proteins 
that can be glutathionylated such as actin, PTP1B (Barrett et al., 1999), Grx and Trx 
(Klatt et al., 2000). Glutathionylation efficiently inhibits actin polymerization and 
accordingly affects the cellular cytoskeleton structure (Dalle-Donne et al., 2003; 
Wang et al., 2001, 2003). 
Deglutathionylation is the removal of the GSH moiety from proteins when 
the environment becomes more reducing (Findlay et al., 2005). Apart from Grx1, 
Srxn1 was found to also deglutathionylate actin, PTP1B and 2-Cys Prxs in addition 
to its role in reversal of Prx hyperoxidation (Findlay et al., 2005, 2006; Park et al., 
2009) (Figure 1.5).  
 
1.6.1.3 Srxn1 as a Prx denitrosylase 
Both catalytic and resolving Cys of Prx I-IV not only can be oxidized by peroxides, 
it can also be S-nitrosylated by nitric oxide (NO), which has been shown to play an 
important role in neurodegeneration (Giasson et al., 2000; Lin and Beal, 2006), to 
form a SNO-Prx protein (Figure 1.5, Engelman et al., 2013; Fang et al., 2007). Prx I 
was found to be nitrosylated in endotoxin-stimulated macrophages as well as nitroso-
cysteine treated epithelial cells and endothelial cells (Benhar et al., 2010; Forrester et 
al., 2009; Lam et al., 2010; Martinez-Ruiz and Lamas, 2004). Fang and co-workers 
(2007) demonstrated that Prx II is S-nitrosylated in vitro, in cell-based models of PD, 
and in human PD brain tissue. Nitrosylation of Prx leads to the loss of Prx peroxidase 
activity (Engelman et al., 2013). An exciting, recent report demonstrated that Srxn1 
can reactivate the enzyme by converting the Cys-SNO of Prx II to Cys-SH in an 
ATP-dependent manner (Sunico et al., 2016). Therefore, Srxn1 is considered as a 
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master regulator of the cell redox state that involves ROS and RNS as it reactivates 
both Prx-SO2H and Prx-SNO.  
 
 
 
Figure 1.5: The enzymatic functions of Srxn1. 
 
 
 
1.6.2 Distribution of Srxn1 in human tissues 
Srxn1 is a ubiquitous protein with significant differences in abundance among human 
tissues (Chang et al., 2004). It is most abundant in kidney, lung, liver, and spleen 
followed by brain, colon, lymph node, placenta, spinal cord and thymus when 
detected by Western blot. Furthermore, Srxn1 was only detected in the cytosolic 
fraction of HeLa cell. However, immunohistochemistry data has revealed a slightly 
different tissue distribution pattern for human Srxn1 (Table 1.2) (Wei et al., 2013). 
For example, Srxn1 was detected in whole brain lysates by Western blot but not in 
the cerebellum by immunohistochemistry. This implied that Srxn1 might only be 
expressed in specific parts of the brain. 
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Table 1.2: An overview of protein expression of Srxn1 in normal human tissues 
analysed by immunohistochemistry. 
Proteine expression of Srxn1 in normal human tissues 
Pancrease √ (highly) Lung × 
Liver √ (highly) Mesothelium × 
Kidney √ (weakly) Ovary × 
Stomach √ (weakly) Peripheral nerves × 
Adrenal gland × Prostate × 
Breast × Retina × 
Cardiac & 
skeletal muscle 
× Small intestine × 
Cerebullum × Spleen × 
Colon × Thymus × 
Endometrium × Thyroid × 
Esophagus × Tonsil × 
Larynx ×   
√ = expressed; × = not expressed 
 
1.6.3 Protective role of Srxn1 
Srxn1 has been demonstrated to have protective antioxidant activity induced by Nrf2 
pathway under condition of oxidative stress (Table 1.3). It protects cells from 
oxidative stress-induced injury in lung (Bae et al., 2009; Singh et al., 2009) and liver 
(Bae et al., 2011, 2012). Additionally, increased Srx expression also is linked to 
oncogenic transformation (Lei et al., 2008). Its role in the protection of neurons from 
mitochondrial dysfunction (Wu et al., 2012), oxidative trauma (Papadia et al., 2008; 
Soriano et al., 2008) and NO-induced hypersensitivity to oxidative stress (Sunico et 
al., 2016) has also been proposed. Neuroprotective agents such as caffeine 
(Endesfelder et al., 2017) found to be able to upregulate the gene expression of Srxn1. 
Srxn1 inhibitors suppressed the growth of tumor in a ROS-mediated mechanism 
(Kim et al., 2016). In conclusion, enhanced Srxn1 expression promotes cell survival 
and proliferation. 
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Table 1.3: A summary of Srxn1 expression and its effect in oxidative stress-induced 
injury models. 
Experimental model Outcomes References 
In vivo studies   
Hepatotoxin (pyrazole)-
injected mice 
Nrf2-dependent upregulation 
of Srxn1 mRNA and protein 
in liver 
Bae et al., 2012 
Ethanol-fed mice Nrf2-dependent upregulation 
of Srxn1 mRNA and protein 
in liver 
Bae et al., 2011 
Mice exposed to hyperoxia Nrf2-dependent upregulation 
of Srxn1 mRNA and protein 
in lung tissue 
Bae et al., 2009 
6-day-old Wistar rats exposed 
to hyperoxia 
- Caffeine 
administration 
Upregulation of Srxn1 mRNA 
and protein in brain tissue 
Decreased Srxn1 protein to 
basal level  
Bendix et al., 
2012; 
Endesfelder et al., 
2017 
Sulfur mustard exposed 
patients 
Upregulation of Srxn1 mRNA 
in sulfur mustard-injured lung 
Tahmasbpour 
Marzony et al., 
2016 
Hypercholestrolemic male 
Westar rat 
Upregulation of Srxn1 mRNA 
in liver tissue 
Al-Rejaie et al., 
2013 
Streptozotocin induced 
diabetic rat 
Upregulation of Srxn1 protein 
level in myocardium via AP-
1 pathway 
Shi et al., 2017 
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Table 1.3: A summary of Srxn1 expression and its effect in oxidative stress-induced 
injury models. (Cont’d) 
Experimental model Outcomes References 
In vitro studies   
A549, HeLa and HEK293 
exposed to hyperoxia 
No upregulation of Srxn1  Bae et al., 2009 
High glucose treated primary 
neonatal rat cardiomyocyte 
and H9c2 cell line 
- Silencing of Srxn1  
Upregulation of Srxn1 protein 
expression 
 
Increased ROS level and Prx 
hyperoxidation 
Shi et al., 2017 
Hypoxia-reoxygenation 
treated H9c2 
- Overexpression of 
Srxn1  
- Siliencing of Srxn1 
Downregulation of Srxn1 
mRNA and protein 
Protect cells from 
mitochondrial apoptosis 
Decreased cell viability in 
hypoxia-reoxygenation 
condition 
Zhang et al., 
2016 
DETA-NO treated 
macrophages 
Upregulation of Srxn1 protein 
via Nrf2 activation 
Abbas et al., 
2011 
Overexpression of Srxn1 in 
H2O2-treated SH-SY5Y and 
pesticides-treated human-
induced pluripotent stem cells 
derived dopaminergic neurons 
Decreased number of 
apoptotic neurons 
Sunico et al., 
2016 
Srxn1 inhibitor treated A549 Caused intracellular ROS 
accumulation, mitochondrial 
damage and apoptosis 
Kim et al., 2016 
Cigarette smoke extract 
treated primary mouse lung 
fibroblasts and A549 cells 
Caused ROS production, 
apoptosis, and upregulation 
of Srxn1 mRNA (not via 
Nrf2) 
Sarill et al., 2015 
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1.7 Project overview: hypotheses and aims of project 
Prior to developing therapeutic approaches for neurodegenerative diseases, it is 
important to gain a better understanding of the cell death mechanisms induced in 
well differentiated neurons. Three observations are key to this study: 1) 
mitochondrial dysfunction is the common feature in different types of 
neurodegenerative diseases; 2) neurons in the dying process often present a complex 
picture reflecting a struggle between pro-death factors and pro-survival responses; 
and 3) Srxn1 is protective under condition of oxidative stress. Therefore, we 
hypothesize that 1) the identification of the sequential order of pro-apoptotic and 
anti-apoptotic factors and responses occurring during rotenone-mediated neuronal 
death is a crucial step to the prevention and treatment of neurodegenerative diseases; 
2) Srxn1 might be able to attenuate rotenone-mediated neuronal cell death.  To 
support these hypotheses, this project will address the following aims: 1) To gain an 
insight into the sequential cellular events in rotenone-mediated neuronal death; 2) To 
identify a potential neuroprotective target in neuronal death; 3) To demonstrate the 
ability of Srxn1 to attenuate rotenone-mediated neuronal death. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Primary neuronal culture 
The preparation of cultured neocortical neurons was performed as previously 
described (Cheung et al., 1998). Foetal cortices of C57BL/6 mice (gestational days 
15 or 16) were microdissected and were subjected to trypsin digestion and 
mechanical trituration and centrifugation. The pelleted cells were resuspended in 
NeurobasalTM medium (NBM) containing 2.5% B-27 supplement, 1% penicillin, 1% 
streptomycin, 0.25% GlutaMAX-1 supplement. Cells were seeded on poly-D-lysine 
(100μg/ml) coated 24-well plates to a density of 4×105 cells/well and were 
maintained at 37˚C in a humidified 5% CO2 and 95% air incubator. More than 95% 
of the cells on day 7 in vitro (DIV 7) cultures were neurons with minimal 
contamination by glia as revealed by immunocytochemical staining for microtubule-
associated protein-2 and glia fibrillary acidic protein. Deakin University Animal 
Welfare Committee (A89-2011) approved all animal studies conducted during this 
project.  
 
2.2 Drug preparation and treatment 
Rotenone (Sigma-Aldrich) was prepared as 10 mM stock solution in DMSO and 
stored at -20˚C. A working concentration of 10 μM was prepared freshly each time 
before use in appropriate culture medium.  
 
2.3 Total RNA extraction and isolation 
RNeasy Mini Kit (Qiagen Cat. No. 74104) was used to extract RNA from cultured 
cells according to the manufacturer’s instructions. RNA concentration was 
determined spectrophotometrically using Nanodrop ND-1000 Version 3.2.1 and 
RNA quality was analysed using E-gene HDA-GT12 genetic analyser. 
 
2.4 Microarray using Illumina Mouse Ref8 Ver.1.1 hybridization beadchips 
Microarray was carried out using Illumina® Mouse Ref8 Ver.1.1 arrays and 
Illumina® TotalPrep RNA Amplification Kit. Each RNA sample (500 ng) was used 
to synthesize double-stranded cDNA according to manufacturer’s instructions. 
Double-stranded cDNA was purified and used as a template for biotinylated cRNA 
synthesis. Biotinylated cRNA (5μl, 750 ng) was mixed with 10 μl hybridization 
buffer and incubated at 65˚C for 5 min. After incubation, the mixture was fully 
loaded onto the large sample port of each array on the beadchip that was then 
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incubated in a humidified hybridization chamber at 58˚C for 17h. The following day, 
the IntelliHyb seal on the beadchip was removed to expose all the arrays. Beadchips 
were blocked and labelled with streptavidin-Cy3, followed by stringency buffer 
washes and dried according to the manufacturer’s instruction (Illumina Inc.). 
Beadchips were scanned on the Illumina scanner using Bead Studio software at Scan 
Factor = 0.8. 
 
2.5 Microarray data analysis 
Differential gene expression: The absolute data (signal intensity, detection call and 
detection P value) were exported into GeneSpring(tm) GX 7.3 (Agilent Technologies, 
San Diego, CA, USA) software for analysis by parametric test based on crossgene 
error model. One-way ANOVA approach was used to identify differentially 
expressed genes. Array data were globally normalized using GeneSpring software. 
After per chip normalizations and per gene normalization, genes were filtered on fold 
change ± 1.2-fold against controls in at least one of three time point conditions. 
Finally, one-way ANOVA approach (P < 0.05) and Benjamini-Hochberg FDR 
Correction were used to find differentially expressed genes.  
Functional analysis of differentially expressed genes: Genes which were 
differentially expressed are annotated using Database for Annotation, Visualization, 
and Integrated Discovery (DAVID) V6.7 (http://david.abcc.ncifcrf.gov/), a gene set-
based algorithm that detects functionally related genes in lists of genes ordered 
according to differential expression. DAVID can search blocks of functionally 
related genes according to different criteria such as the Gene Ontology terms 
biological process and cellular component. Briefly, a list of differentially expressed 
gene ID was submitted to DAVIDA FDR of <0.05 was considered statistically 
significant. PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) searches were 
performed to validate the clusterings given by DAVID and also to provide 
information on how individual biological processes were networked.  
All microarray data reported here are described in accordance with MIAME 
guidelines and have been deposited in NCBIs Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession 
number (Rotenone, GSE22997; NMDA, GSE16035; Lactacystin, GSE22465).  
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2.6 Real-time PCR 
Six differentially expressed genes were selected for validation of the microarray 
results by quantitative real-time PCR. Microarray biological triplicates were 
combined into one sample for subsequent analysis in duplicate per probe. The same 
total RNAs used for microarray from mouse culture treated with 10 nM rotenone 
were reverse transcribed to cDNA according to steps specified by the manufacturer 
(Applied Biosystems Taqman reverse transcription reagents). The experiment set up, 
briefly, consisted of Taqman master mix (20µl) and cDNA or water (non-treated 
control; both 5µl) was added to the designated reaction well. The plate was then read 
using the 7000 Fast Real-Time PCR System with conditions according to the 
manufacturer’s protocol. 
 
2.7 Production of His-tagged mouse Srx1 recombinant protein 
The glycerol stock of Escherichia coli (E. coli) strain Rosetta 2 (BL21) carrying 
pET-Duet1-Srxn1 (WT)-His plasmid (prepared by Dr Jeremy Ng) (Figure 2.1) was 
revived and cultured in 50 mL LB medium at 37°C for overnight. Two litres 2x-YT 
media containing 100 µg/mL amphicillin was inoculated with 50 mL overnight 
bacterial culture and grown at 37°C with shaking at 170 rpm. When the culture 
reached OD600 ~ 0.6, isopropyl-β-D-1-thiogalactopyranoside (IPTG) was added to a 
final concentration of 0.5 mM, and growth continued overnight at 25°C. The cells 
were then harvested by centrifugation at 10,000 rpm at 4°C for 30 min. The bacterial 
pellet was resuspended and lysed with 100 ml chilled lysis buffer (100 mM NaH2PO4, 
10 mM Tris-Cl, and 8 M urea, pH8.0) and sonicated on ice with 6 short burst of 20 
sec with intervals of 30 sec for cooling. Again, the lysate was centrifuged at 10,000 
rpm at 4°C for 30 min and the supernatant was incubated with 2 ml HisLink™ 
Protein Purification resin (Promega), which was pre-washed with lysis buffer, at 
room temperature for 1 h with shaking. The mixture was then passed through a glass 
gravity column. The column was washed three times with 100 ml wash buffer (100 
mM NaH2PO4, 10 mM Tris-Cl, and 8 M urea, pH 6.3). Finally, the recombinant 
protein was eluted with 8 ml of elution buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 8 
M urea, pH4.5). Fractions of one mL were collected. Protein concentrations were 
determined with Pierce™ BCA Protein Assay kit. Protein purity was checked by 
separating 20 μl of each fraction and flow-through on a 15% reducing 
polyacrylamide gel and subjected to Coomassie staining.  
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Figure 2.1: Bacterial protein expression vector, pETDuet-1 plasmid map. C-terminal 
His-tagged mouse Srxn1 was inserted between NcoI and EcoRI. 
 
 
2.8 Western Blot 
Proteins were extracted using lysis buffer containing 50 mM HEPES, 0.5% NP-40, 
0.5% Triton-X-100, 50 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM DTT and 
protease inhibitor cocktail tablet (Roche Diagnostics GmbH, Mannheim,Germany), 
and the supernatant (lysate) was collected after centrifugation at 13,000 rpm for 
10min at 4°C. Protein concentrations were determined with Pierce™ BCA Protein 
Assay Kit. Equal amounts of protein were separated in a polyacrylamide gel and 
transferred to polyvinylidene difluoride (PVDF) membrane. Immunodetections were 
performed using primary and secondary antibodies (Table 2.1). The membrane was 
incubated with primary antibody at 4°C overnight with shaking followed by washing 
three times with TBST and incubated with secondary antibody for 1 h at room 
temperature and washed again with TBST. Signals were detected using Millipore 
Immobilon Western horseradish peroxidase (HRP)-conjugated substrate and BioRad 
Chemidoc MP. 
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Table 2.1: List of primary and secondary antibodies used for western blot.  
Protein Primary/s
econdary 
Species 
raised in  
Dilution Source 
Srxn1 Primary mouse 1:100 Santa Cruz 
Srxn1 Primary rabbit 1:1000 Proteintech 
Active caspase-3 Primary rabbit 1:1000 BD PharMingen 
Flag Primary mouse 1:1000 Sigma 
α-fodrin Primary mouse 1:1000 Chemicon 
β-tubulin Primary mouse 1:1000 Sigma 
Prx II Primary mouse 1:1000 Abfrontier 
Prx-SO3 Primary rabbit 1:1000 Abfrontier 
β-actin Primary mouse 1:1000 Sigma 
Anti-mouse HRP secondary goat 1:5000 Dako 
Anti-rabbit HRP secondary goat 1:10000 Dako 
HRP: horseradish peroxidase-conjugated 
 
 
2.9 Bacterial transformation and plasmid isolation  
Plasmids: The pLVX-Tet-On Advanced plasmid was from Clontech and all the 
mouse and human Srxn1 cloned in pLVX-Tight-Puro vector were purchased from 
GeneArt (Figure 2.2). Genes were cloned into the BamHI and EcoRI sites of pLVX-
Tight-Puro vector. 
Bacterial transformation: All the lentiviral vectors were transformed into One 
Shot™ Stbl3™ Chemically Competent E. coli (Invitrogen). Plasmid DNA (1-5ng) 
was added into a vial of Stbl3 cells and incubated on ice for 30 min. Cells were heat-
shocked at 42°C for 45 sec and placed on ice for 2 min, and followed by the addition 
of 250 μl of pre-warmed S.O.C medium (Invitrogen) to each vial and incubation at 
37°C for 1 h with shaking. Later, the culture (10-50 μl) was plated on Luria-Bertani 
(LB) agar plate containing 100 μg/ml ampicillin and incubated at 30°C overnight. 
One single colony from each plate was inoculated into 5 ml LB medium containing 
100 μg/ml ampicillin and cultured at 30°C overnight. Next day, the starter culture 
(200 μl) was transferred to a flask containing 100 ml LB and ampicillin and cultured 
at 30°C overnight.  
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Plasmid isolation: Plasmid DNA was isolated and purified from the overnight 
bacterial culture (Section 2.9) with the Qiagen® Plasmid Midi Kit. Bacterial culture 
(100 ml) was centrifuged at 5000 rpm for 20 min at 4°C. The pellet was then lysed 
and processed following the manufacturer’s instructions. The plasmid DNA was 
resuspended with 240 μl H2O. The DNA concentration was measured using a 
NanoDrop 1000. Plasmid DNA was digested with appropriate restriction enzymes 
and run on a 0.8% agarose gel for verification.  
 
Figure 2.2: Plasmid maps of (A) pLVX-Tet-On Advanced and (B) pLVX-Tight-Puro. 
 
 
2.10 Transient co-transfection for mouse cortical neurons 
The purified pLVX-Tet-On Advanced and pLVX-Tight-Puro-mSrxn1-eGFP were 
co-transfected into primary cortical neurons. Cultured primary cortical neurons were 
seeded and allowed to attach overnight before co-transfection. Transfection was 
performed using Lipofectamine 2000 (Invitrogen) on DIV 1 (Day In Vitro 1). For 
each well in a 24-well plate, transfection mixtures were prepared as outlined in Table 
2.2. Diluted DNA (0.5 μg) was transferred to a microfuge tube containing diluted 
Lipofectamine 2000 and incubated for 5 min at room temperature. The old culture 
medium was removed and replaced with 200 μl/well NBM containing 2.5% B-27 
and 0.25% Glutamax. The transfection mix (50 μl) was added dropwise into the well 
and incubated for 3h at 37°C. The transfection mix was removed and fresh culture 
medium (1 ml/well) was added. Srxn1-eGFP expression was induced by adding 1 
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μg/ml doxycycline (Dox) on DIV 4 and incubated for another 2 days before 
subsequent experiments. 
 
Table 2.2: Preparation of Lipofectamine 2000 transfection mix.  
Steps Component Volume (μl) 
Dilute Lipofectamine 2000 
reagent 
Lipofectamine 2000 1.5 
 Opti-MEM 25 
Dilute plasmid DNA  Tet-On Advanced and 
mSrxn1-eGFP 
0.25 μg and 0.25 μg 
 Opti-MEM 25 
 
 
2.11 Immunofluorescence staining 
Cells were plated on poly-D-lysine-coated coverslips. All the staining solutions were 
prepared in PBS and all the steps of immunostaining were performed at room 
temperature unless otherwise stated.  
Culture medium was removed and cells on coverslips were fixed with 4% 
paraformaldehyde (PFA) for 10 min at room temperature and then washed 5 times in 
PBS. After fixing, the cells were permeabilized with 0.1% Triton X-100 for 10 min 
and washed with PBS. The permeabilized cells were blocked with 1% BSA and 
0.25% gelatin for 20 min and washed with PBS. The cells were incubated with 
primary antibody (Table 2.3) diluted in 1% BSA in PBS overnight at 4°C. Next day, 
the coverslips were washed with PBS prior to the incubation with secondary 
antibody (Table 2.3) diluted with 1% BSA in PBS for 1 h. Nuclei were stained with 
Hoechst 33342 dye (Sigma; 5 μg/ml) for 5 min incubation and washed with PBS. 
The coverslips were mounted onto a glass slide. Images were visualised using a 
fluorescence microscope (Leica) coupled to a digital camera.  
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Table 2.3: List of primary and secondary antibodies used for immunostaining.  
Protein Primary/sec
ondary 
Species 
raised in  
Dilution Source 
Srxn1 Primary rabbit 1:1000 Proteintech 
Flag Primary mouse 1:1000 Sigma 
Anti-mouse 
AlexaFluor  
secondary goat 1:1000 Molecular Probe 
Anti-rabbit 
AlexaFluor 
secondary goat 1:1000 Molecular Probe 
 
 
2.12 SH-SY5Y cell culture 
Undifferentiated human neuroblastoma SH-SY5Y cells (CellBank, Australia) were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM): Ham’s F12 (1:1) (Gibco) 
containing 15% fetal bovine serum (FBS; Bovogen), 1% non-essential amino acid 
(NEAA) (Gibco) and 0.2% penicillin/streptomycin (PS) (Gibco). Cells were 
incubated at 37°C and 5% CO2 in 75 cm2 flasks and split to sub-confluent cultures at 
a ratio of 1:10 to 1:15 with growth medium a change every 3-4 days. Cells were used 
under 20 passages and maintained at below 80% confluence. 
 
2.13 Generation and maintenance of SH-SY5Y cells expressing Flag-Srxn1, 
differentiation, and treatments 
Generation and maintenance: The lentiviral tetracycline inducible expression 
systems (Clontech) were used to generate stably induced SH-SY5Y cell lines 
exhibiting tetracycline-inducible expression of Flag-hSrxn1-eGFP, Flag-hSrxn1 or 
hSrxn1-Flag. Briefly, SH-SY5Y was seeded onto a 6-well plate (3.5 – 7 × 105 
cell/well) and cultured at 37°C until the cell reached a confluency of at least 60%. 
SH-SY5Y cells were transfected with pLVX-TetOn advanced plasmid using 
Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instruction. 
Transfection mix preparation was summarized in Table 2.4. The old medium was 
removed from each well and 1 ml serum-free medium (DMEM/F12 and 1% NEAA) 
was added and followed by 0.25 ml transfection mix and incubation at 37°C for 2 h. 
At the end of the incubation, 1.25 ml medium (DMEM/F12, 30% FBS and 1% 
NEAA) was added to each well. Cells were cultured for another 48-72 h at 37°C to 
30 
 
allow for the incorporation of the gene into the genome. Later, the transfection 
medium was removed and replaced with 2 ml/well fresh growth medium 
(DMEM/F12, 15% FBS, 1% NEAA and 0.2% PS) and cells were cultured at 37°C 
for 72 h to allow for expression of the antibiotic resistant gene.  
 
 
Table 2.4: Preparation of Lipofectamine 3000 transfection mix. 
Steps Component Volume (μl) 
Dilute Lipofectamine 3000 reagent Lipofectamine 3000 7.5 
 Opti-MEM 125 
Dilute plasmid DNA  Plasmid DNA 2.5 μg 
 Opti-MEM 125 
 P3000 5 
 
For antibiotic selection: Tet-On Regulatory Stable line was selected with 
DMEM/F12 containing 15% FBS, 1% NEAA, 0.2% PS and 500 μg/ml G418 for 8 
days. Cells were maintained as polyclonal batches post-transfection and analysed by 
transiently transfecting with pLVX-TightPuro-eGFP and visualisation under a 
fluorescence microscopy.  
The regulator-positive batch of cells were then transfected with pLVX-
TightPuro-Flag-hSrxn1-eGFP, pLVX-TightPuro-Flag-hSrxn1 or pLVX-TightPuro-
hSrxn1-Flag plasmid using Lipofectamine 3000 as mentioned above. Later, cells 
were selected with 2 μg/ml puromycin 48 h post-transfection for 14 days. To induce 
protein expression, cells were cultured in medium containing 1 μg/ml Dox for at least 
24h. The expression of recombinant proteins were validated with western blot and 
immunostaining. The double-stably transfected SH-SY5Y cell lines were maintained 
in DMEM/F12 with 15% FBS, 1% NEAA, 0.2% PS, 100 μg/ml G418 and 0.75 
μg/ml puromycin.  
Differentiation: To differentiate the SH-SY5Y cells, 1.8 × 104 cells were seeded 
into a 24-well plate per well. Twenty-four hours after seeding, cells were 
differentiated with 10 μM retinoic acid (RA) (Sigma) in DMEM/F12 containing 5% 
FBS for the first 3 days followed with 50 ng/ml brain-derived nerve growth factor 
(BDNF) (Sigma) in serum-free DMEM/F12 (Knaryan et al., 2014) for the next 3 
days at 37°C.  
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Treatment: Different concentrations of rotenone (0.1, 0.5, or 1 μM) were used to 
expose the cells for a period of 7 days. To test cytoprotection, cells were treated with 
both rotenone and Dox.  
 
2.14 Cell viability assay 
Cell viability was assessed with the Cell Counting Kit-8 (CCK-8) (Invitrogen). 
Following treatments, the CCK-8 solution (25 μl) was added to each well and cells 
were incubated for 24 h at 37°C. The optical absorbance at 450 nm for each sample 
was measured using an absorbance microplate reader (FLUOstar Omega, BMG 
Labtech). The percent viability was calculated with viability in vehicle control cells 
considered as 100%.  
 
2.15 Statistical methods 
One-sample t-test or one-way ANOVA with post hoc test were carried out to assess 
the significance of data. 
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CHAPTER 3 
THE SEQUENTIAL CELLULAR EVENTS IN 
ROTENONE-MEDIATED NEURONAL DEATH 
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3.1 Introduction 
In this chapter, the signalling cascade of rotenone-mediated neuronal cell death is 
studied with the combination of microarray technology and the bioinformatics 
analysis tool, Database for Annotation, Visualization, and Integrated Discovery 
(DAVID) in a well-established in vitro rotenone model (Chen et al., 2006) from our 
laboratory (Figure 3.1). This approach has been extensively used in our laboratory to 
study the temporal order of cellular pathways during neuronal death triggered by a 
number of neurotoxins (Chen et al., 2011, 2013; Ng et al., 2012; Peng et al., 2012).  
 
 
 
 
Figure 3.1: Flow of microarray and bioinformatic analyses. cDNA was reverse 
transcribed from harvested total RNA and was labelled with fluorescent dyes. The 
labelled cDNA was hybridized to gene chip and the fluorescent signal was detected 
with a scanner. The raw data obtained after scanning was subjected to Genespring 
analysis and was converted to expression fold-change. Only those genes with ± 1.2 
fold-change in at least one of three time points were selected and were annotated. 
Each group of genes was subjected to functional process analysis by DAVID and 
PubMed search.   
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3.2 Gene expression during rotenone-induced neuronal apoptosis 
Our lab has previously shown that in rotenone induced PCD in mouse primary 
cortical neurons, calpain activation precedes caspase activation during cell (Chen et 
al., 2006). The key to understanding the temporal order of cell death mechanisms is 
to obtain rotenone-induced neuronal transcripts from different time points. Primary 
cortical neurons were treated with 10 nM rotenone for 8, 15 and 24 h. The RNA was 
harvested and used for DNA microarray and bioinformatic analyses. Out of a total of 
24,613 well-annotated RefSeq transcripts, 4718 RefSeq transcripts with a minimum 
gene expression of ± 1.2-fold change in at least one of the three time-points were 
considered to be significantly regulated. As shown in Figure 3.2, the number of 
down-regulated genes in murine cortical neurons treated with rotenone increased 
substantially after the 8 h time-point, while the number of up-regulated genes 
remained unchanged across the three-time points. Within these down-regulated gene 
probes, the number of genes with fold-change difference above 1.2 significantly 
increased from 644 (8 h) to 3727 (24 h). This tremendous increase was attributed to 
the expansion of the ≥2-fold change category from the initial 14 genes (8 h) to an 
escalating 1465 genes (15 h), and a slow steady increase to 1777 genes (24 h). As 
such, it can be inferred that the most significant transcriptional regulation occurred 
between 8 h and 15 h.  
 
 
3.3 Functional categorization of neuronal death-related differentially-expressed 
genes 
As decribed in Figure 3.1, the differentially expressed genes in each time point were 
annotated by DAVID 6.7 and PubMed searches to categorize them into functional 
groups. There were nine biological processes affected following rotenone-mediated 
neuronal injury and these are summarized in Table 3.1 and the complete list of 
differentially-expressed genes is shown in Appendix A. Gene symbols in the text are 
in italics and proteins are not italicized. 
 
3.3.1 Mitochondrial dysfunction 
As a mitochondrial complex I inhibitor, rotenone not only affected the transcripts of 
complex I (Ndufa5, Ndufa9, Ndufb8 and Ndufs3) (Appendix A), but also the 
expression of many other mitochondrial genes encoding proteins located at IMM and 
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OMM. The downregulation of gene expression started as early as 8 h for genes 
functioning at the IMM and at 15 h for those genes residing at OMM. Genes affected 
by rotenone also function in electron transport chain (ETC) (Atp5o, Cox8b, Cyc1, 
Uqcrc1 and Uqcrc2) and cell death signalling (Bad, Bcl2l1 and Bcl2l2). Therefore, 
inhibition of complex I by rotenone results in mitochondrial and bioenergetic failure, 
ultimately leading to PCD.  
 
 
 
 
 
 
Figure 3.2: An overview of total numbers of genes showing at least ± 1.2 fold 
change in rotenone treatment at 8 h, 15 h and 24 h, respectively. (Taken from Yap et 
al., 2013)  
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Table 3.1. A summary of most prominently affected biological pathways. Unaffected 
= fold-change less than 1.2 
Biological pathways 8 h 15 h 
Mitochondrial dysfunction 
   Inner mitochondrial membrane 
   Outer mitochondrial membrane 
 
↓ 
Mostly unaffected 
 
↓ 
↓ 
Calcium signalling ↑↓ ↑↓ 
Unfolded protein response ↑ ↓ 
GSH metabolism ↓ ↑ 
Ubiquitin-proteasome system Mostly unaffected ↓ 
Chaperones/co-chaperones Mostly unaffected ↓ 
Apoptogenic signalling Mostly unaffected ↑ 
Autophagy-lysosome system 
   Autophagy machinery 
   Lysosomal enzyme 
Mostly unaffected  
↓ 
↑ 
Oxidative stress response via Nrf2 
pathway 
↑↓ ↑ 
 
 
3.3.2 Apoptogenic signaling 
Most of the apoptosis-related genes (Bcl2, casp8, Nradd, Tnfrsf1a, Tnfrsf6 and 
Tnfrsf19) remain unaffected (< ±1.2-fold) at 8 h but their expression was increased at 
15 h.  Changes in the expression of caspases were not found at early time points. 
 
3.3.3 Calcium signaling  
Disruption of mitochondrial membrane potential leads to Ca2+ release from 
mitochondria-controlled stores. Blocking mitochondrial ATP production additionally 
raises cytosolic Ca2+ levels through the inhibition of ATP-dependent calcium pumps 
such as plasma membrane Ca2+-ATPase (PMCA) and sarco/endoplasmic reticulum 
Ca2+-ATPase (SERCA) (Landolfi et al., 1998). Calpain activation, an indirect 
indication of disturbance of calcium homeostasis, was observed as early as 5h in our 
previous study (Chen et al., 2006). However, rotenone does not seem to alter calpain 
expression at the transcript level. Reduced expression of Calb2, a mobile calcium 
buffering protein at 15 h, further supports the disruption of calcium homeostasis. 
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Additionally, the transcripts of CaM-kinases (Camk1d, Camk1g, Camk2a, Camk2b 
and Camk2g) were slightly increased at 8h but decreased at 15 h while the transcripts 
of annexins (Anxa2, Anxa3 and Anxa5) and S100 calcium binding proteins (S100a1, 
S100a4, S100a6 and S100a11) were downregulated at 8 h and upregulated at 15 h.  
 
3.3.4 Ubiquitin Proteasome system (UPS) 
As ATP is required by ubiquitin-activating enzymes, decreased ATP production may 
compromise function of the UPS. Rotenone treatment down-regulated the transcripts 
of all the UPS players such as ubiquitin-conjugating enzymes (Ube2d3, Ube2n and 
Ube2z), ubiquitin ligase (Btrc, Ube3b and Ube3c), proteasome (Psma1, Psmb1 and 
Psmd8), proteasome regulator (Psme2), and deubiquitinating enzymes (Usp12 and 
Usp21) at 15 h.  
 
3.3.5 Chaperones/co-chaperones 
Protein misfolding has been implicated in the pathophysiology of several 
neurodegenerative disorders (Jellinger, 2012). Most of the transcripts of genes 
encoding chaperones (Hsp105, Hspa8 and Hspb3) and co-chaperones (DnaJ family 
and FKbp) were significantly downregulated after 15 h.  
 
3.3.6 Unfolded protein response (UPR) 
Accumulation of damaged or unfolded protein as a result of oxidative stress and 
dysfunction of UPS can lead to UPR (Nagley et al., 2010). Previous studies have 
shown activation of the UPR after oxidative stress was induced in neuronal cells 
using high toxin concentrations that resulted in 50% cell death within 24 h (Holtz et 
al, 2006; Ryu et al., 2002). We observed similar effects, with 10 nM rotenone 
causing upregulation of Atf4, Cebpb, Ddit3, Ern2 and Myd116 indicating the 
activation of UPR in neurons as early as 8 h after treatment.  
 
3.3.7 Autophagy-lysosome pathway 
In addition to UPS, autophagy, a lysosome-mediated degradative pathway, is a 
cellular mechanism responding to bioenergetic crisis, damaged organelles and 
misfolded proteins. Inhibition of autophagy has been shown to cause 
neurodegeneration in mice (Hara et al., 2006; Komatsu et al., 2006). Here, lysosomal 
proteins such as cathepsins, CD antigens, metallothioneins, Fnbp1, Asah1, Lamp2, 
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Laptm5 and NPC2 were upregulated at 15 h. Surprisingly, autophagy machinery 
components such as Atgs, AMBRA1, Becn1, Dapk1, Crmp1, Gabarapl1, Map1lc3a, 
Map1lc3b and Rab24 were down-regulated at 15 h. These diverse changes suggest 
considerable adaptations in the UPS-autophagy interface subsequent to disruption of 
mitochondrial complex I (Nagley et al., 2010). 
 
3.3.8 Glutathione metabolism  
Consistent with reports that inhibition of complex I increases ROS production and 
leads to oxidative stress, the expression of genes involved in GSH metabolism such 
as Gclm, Gst and Ugt1a6a was decreased at 8 h and significantly upregulated after 
15 h. Arl6ip5 has been reported to negatively and dominantly regulate cellular GSH 
content (Watabe et al., 2007), and was found here to be down-regulated at 15 h while 
the cells attempted to increase other genes involved in GSH metabolism. However, 
Slc1a1 expression (neuronal cysteine transporter) was decreased throughout the 
treatment.  
 
3.3.9 Defence against oxidative stress (via nuclear factor erythroid 2-related factor 
2 (Nfe2l2) pathway) 
The transcription factor Nfe2l2 and the Nrf2 anti-oxidant response element are at the 
forefront against oxidative stress (Kanninen et al., 2011). During oxidative stress, 
Nfe2l2 induces the expression of genes encoding detoxifying enzymes and 
antioxidants. The activation of Nfe2l2 pathway is clearly evident (Appendix A). 
Nfe2l2 was increased 3.5-fold at 15 h while its inhibitor, Keap1, was downregulated. 
In addition, some of the well-characterized cytoprotective genes controlled by Nfe2l2, 
including Gclm, Gss, Hmox1, Nqo1 and Srxn1, were found upregulated at 15 h. Our 
findings indicate that Nfe2l2 pathway was activated at 15 h as a protective 
mechanism against oxidative stress.  
 
 
3.4 Validation of microarray analysis 
Real-time PCR using gene-specific probes was performed on the same rotenone-
treated neuronal samples used in the microarray analysis. Six genes (Anxa2, Atf3, 
Hmox1, Hspb8, Ier3 and Srxn1) were selected for validation. These selected genes 
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probes demonstrated identical/similar transcriptional trends at the 15 h and 24 h time 
points (Table 3.2).  
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Table 3.2. Validation of microarray data using real-time PCR on mouse cortical neurons treated with 10 nM rotenone.  
GenBank Gene Title Symbol                                15 h                              24 h 
   Microarray Real-time 
PCR 
Microarray Real-time 
PCR 
NM_007498 Activating 
transcription factor 3 
Atf3 3.63 ± 0.87 4.77 ± 0.69 9.65 ± 0.75 17.38 ± 0.69 
NM_010442 Heme oxygenase 1 Hmox1 14.26  ± 2.29 9.13 ± 0.86 23.87  ± 1.59 24.68 ± 0.58 
NM_007585 Annexin A2 AnxA2 2.05 ± 0.62  2.76 ± 0.32 4.09 ± 0.58 
NM_133662 Immediate early 
response 3 
Ier3 2.63 ± 0.15 1.90 ± 0.90 8.06 ± 0.78 4.16 ± 0.88 
NM_029688 Sulfiredoxin 1 
homolog 
Srxn1 6.79 ± 1.26 4.08 ± 0.74 9.84 ± 1.63 12.08 ± 0.84 
NM_030704 Heat shock  protein 8 Hspb8 5.08 ± 0.31 3.06 ± 0.97 8.27 ± 0.58 7.39 ± 0.91 
Data are expressed as fold-change ± SE. 
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3.5 Discussion 
Based on the temporal transcriptomic profiling of rotenone-induced neuronal injury 
indicated a novel pattern of recruitment of diverse biological processes linked to key 
homeostatic functions, including those for mitochondrial function, PCD, calcium 
signaling, UPS, UPR, autophagy, GSH metabolism and endogenous oxidative stress 
defence. Although the gene expression profile may not necessarily reflect the level of 
the corresponding proteins, these data are promising for selection of future gene 
therapy and/or drug targets for neurodegenerative diseases that are involved in 
mitochondrial dysfunction. Furthermore, an overview of rotenone-mediated neuronal 
PCD was able to devise from bioinformatic analyses of the pattern of gene 
expression changes based on a time-course of global transcriptomic profiling (Figure 
3.3).   
 
3.5.1 Early events (≤8 h)  
Mitochondrial complex I is a large 850 kDa protein complex composed of about 40 
polypeptide units kept together by non-covalent hydrophobic bonds and van der 
Waals’ weak bonds. Rotenone inhibits complex I electron transfer activity by 
disrupting the hydrophobic bonds, thereby dampening ATP production and increased 
rate of ROS formation (Martinez and Greenamyre, 2012). We found that rotenone-
treated neurons displayed a dramatic decrease in OXPHOS transcripts. This 
observation suggested that the cells have reached the advanced stage of complex I 
inhibition (Greene et al., 2010) at 8 h.  
As well as producing energy and regulating cell death, mitochondria also 
serve functions in calcium storage. Inhibition of mitochondrial complex I de-
energizes mitochondria and cause them to release calcium back to the cytosol. 
Additionally, depletion of ATP also inhibits the function of PMCA and SERCA, and 
leads to release of ER Ca2+ and ER stress as evidenced by the increased expression of 
UPR players (Atf4, Cebpb and Ddit3) at 8h. Low dose rotenone (10 nM) has been 
shown to increase the intracellular free Ca2+ level which was conducive for increased 
expression and activities of Ca2+-activated neutral protease calpain and downstream 
caspase-3 (Samantaray et al., 2011). These data are consistent with our previous 
report where calpain was activated within 5 h after rotenone treatment (Chen et al., 
2006). On the other hand, several S100 calcium binding proteins were down 
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Figure 3.3: Involvement of biological processes in rotenone-mediated neuronal 
death. (Taken from Yap et al., 2013) 
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regulated. Intracellular free calcium overload can lead to over-activation of the 
downstream signalling pathways regulated by calcium. One key signalling pathway 
that is activated by calcium signalling is CaMKII, which has been reported to 
mediate survival of many types of neurons (Bok et al., 2007; Ghosh and Greenberg, 
1995) by phosphorylating and inhibition of BAD and GSK-3, which in turn leads to 
inhibition of caspase-3 activation. Importantly we failed to find evidence for early 
changes in the expression of caspase-3 consistent with our previous finding that 
caspase-3 activation is only noticeable after 21 h (Chen et al., 2006). We also have 
documented that rotenone preferentially redistributes the mitochondrial protein 
apoptosis-inducing factor (AIF) indicative of caspase-independent “death” signalling 
(Lim et al., 2007). 
Transcripts related to GSH metabolism (Gclm, Gsr and Gst) were reduced by 
rotenone treatment consistent with reports that inhibition of complex I increases ROS 
production and leads to oxidative stress (Perfeito et al., 2012). GSH synthesis in 
neurons relies mainly on the transport of extracellular cysteine. The neuronal 
cysteine transporter, Slc1a1, which accounts for ~90% of total cysteine uptake, is 
also downregulated (Aoyama et al., 2006; Chen and Swanson, 2003).  The data 
suggested that rotenone induced oxidative stress by triggering GSH loss via 
inhibition of extracellular cysteine import. 
 
3.5.2 Later events (≥8 h) 
Downregulation of OMM related genes was observed at 15 h after rotenone 
treatment. Rotenone treatment might trigger OMM permeabilization by inducing the 
loss of mitochondrial protein constituents. Indeed, OMM permeabilization as a 
consequence of oxidative stress can lead to caspase-independent redistribution of 
cytochrome c and subsequent caspase-3 activation as evidenced by the cleavage of 
pro-caspase-3 at 21 h (Chen et al., 2006) could be a downstream consequence of 
dysfunctional mitochondria and calpain activation (Esteves et al., 2010; Martinez et 
al., 2010). 
Once mitochondria were beyond repair, apoptotgenic genes were found to be 
upregulated at 15 h. There are two major forms of apoptosis, intrinsic and extrinsic. 
Since rotenone treatment damages mitochondria, it would be expected in theory that 
rotenone-mediated PCD take place via the intrinsic pathway (Nagley et al., 2010). 
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However, while players in extrinsic apoptotic pathway (Nradd, Tnfrsf1a, Tnfrsf6, 
Tnfrsf19 and casp8) increased in expression, the increase of Bcl2 in parallel with the 
downregulation of players involved in the intrinsic pathway (Bad, Cyc1 and Cycs) 
(Appendix A, mitochondrial dysfunction) suggests that the cells attempted to block 
the mitochondrially-mediated PCD pathways.  
Amongst the later events, Camk2b and other members of calcium/calmodulin 
kinase signalling were downregulated. Ashpole et al. (2012) showed that prolonged 
inhibition (> 8 h) of CaMKII produces apoptosis (cleaved caspase-3 was observed) 
in cortical neurons associated with neuronal hyperexcitability and dysregulated 
calcium and glutamate signalling. Concurrently, transcriptional upregulation of 
apoptosis-related annexin (Anxa2 and Anxa3) (Chong et al., 2010; Huang et al., 2008) 
and S100A calcium binding proteins such as S100a6 (Hoyaux et al., 2002; Leclerc et 
al., 2007) further facilitates the development of PCD.  
Prolonged ER stress conditions were found to transcriptional increase Atf4 
expression and consequently induce PCD in part through the Atf4-mediated induction 
of the Ddit3 gene, a transcriptional activator of the C/EBP protein family with pro-
apoptotic properties. Ddit3 is believed to promote the death of stressed cells by 
increasing the load and oxidation of client proteins in the ER through the up-
regulation of Ern2.  
Chaperones act with regulatory co-chaperones to ensure that the synthesized 
proteins are properly folded and to prevent them from forming irreversible 
intracellular aggregation. Proteins that are unsuccessfully folded by chaperones will 
be targeted to and degraded by UPS, a major degradation system for short-lived 
proteins (Hershko and Ciechanover, 1998). Downregulation of all the players of 
chaperones/co-chaperones and UPS (Appendix A, chaperones/co-chaperones, UPS) 
leads to accumulation of damaged and/or obsolete proteins and also malfunctioning 
organelles.  
Unlike the UPS, autophagy is mainly responsible for the degradation of long-
lived proteins and other cellular contents. Although the proteins targeted for 
autophagy and the UPS are different, the two systems serve a similar purpose 
degrading proteins and recycling amino acids. The two cellular degradation systems 
are functionally coupled and suppression of UPS activates autophagy (Ding et al., 
2007). In this context, autophagy functions to purge polyubiquitinated proteins 
induced by proteasome inhibitors and alleviate ER stress. However, a decrease in 
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gene expression of members of the autophagy machinery (Atg4b, AMBRA1, Becn1, 
Crmp1 and Map1lc3) was observed at 15 h of rotenone-mediated apoptosis, 
suggesting that suppression of autophagy can lead to a stronger death signal in the 
cells. This view is supported by other studies where autophagy can be protective 
against cell death and the toxicity of misfolded proteins (Higgins et al., 2010; Janda 
et al., 2012; Lee et al., 2012).  
Cellular efforts to minimize the effect of oxidative stress by reduced 
expression of the Nfe2l2 inhibitor, Keap1 were detected. At 15 h, Nfe2l2 was 
activated and probably translocated to the nucleus to induce gene expression of 
several detoxifying enzymes and antioxidants such as Atf3-5, Gsta2, Gclm, Hmox-1, 
Nqo1, Prdx6 and Srxn1 to increase cellular GSH content and thereby overcome 
cellular oxidative stress.  However, this defence mechanism faced an obstacle, which 
was the several fold downregulation (-6.48 at 15 h; -12.12 at 24 h) of Slc1a1 (rate-
limiting step of neuronal GSH synthesis). Indeed Slc1a1-deficient mice display both 
a low level of neuronal GSH and vulnerability to oxidative stress (Aoyama et al., 
2006). In conclusion, the cells failed to overcome the oxidative stress by de novo 
GSH synthesis that is required for the activity of many antioxidants. Inhibition of 
mitochondrial complex I to alter the expression of genes related to energy 
metabolism, pro-apoptotic and anti-apoptotic pathways (Falk et al., 2009; Greene et 
al., 2010; Meurers et al., 2009). A study using genome-wide meta-analysis of gene 
sets from patients with symptomatic Parkinson's and subclinical disease and healthy 
controls revealed defects in mitochondrial electron transport, glucose utilization, and 
glucose sensing during early disease pathogenesis (Zheng et al., 2010). Therefore, 
transcriptomic profiling is a very useful approach to investigate the cellular pathways 
that are affected during neuronal cell death. However, all of the profiling studies 
done previously have failed to address the temporal order of the cellular pathways 
induced after mitochondrial complex I inhibition. 
 
 
3.6 Conclusion 
Based upon the present study, a molecular mechanism involved in rotenone-mediated 
neurodegeneration has been proposed. By inhibiting complex I, rotenone dampened 
ATP energy production leading to ATP depletion and subsequently blocking the 
function of ATP-dependent calcium pumps. Therefore, cytosolic calcium 
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concentration increased as an early event resulting in calpain activation. Increase of 
intracellular calcium concentration led to the activation of Camk2 and subsequently 
turned off the activity of GSK-3 and Bad by phosphorylation. Therefore, caspase-3 
activation was prevented as a protective mechanism. At the same time, complex I 
inhibition also increased ROS production inducing oxidative stress. In addition, 
transcripts involved in GSH metabolism were reduced by rotenone treatment, 
contributing to oxidative stress. Emptying ER calcium stores and accumulation of 
oxidized proteins in the ER led to UPR as a protective mechanism.   
At the later stage, OMM protein constituents were affected, such that 
eventual rupture of OMM would release mitochondrial inter-space molecules, 
especially cytochrome c and AIF. The survival Camk2 kinases were all shut down at 
the mRNA level. Prolonged activation of UPR can lead to apoptosis (Nagley et al., 
2010). In addition, the machineries needed to ensure the proper protein folding and 
clearance of the misfolded protein such as chaperones, UPS and autophagy were also 
down-regulated. Similarly, gene expression of apoptotic players such as Tnfr, casp8 
and cathepsins, was significantly increased further driving the fate of the cells to 
PCD.  
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CHAPTER 4 
COMPARATIVE MICROARRAY ANALYSIS 
IDENTIFIES SRXN1 AS A CANDIDATE THERAPEUTIC 
TARGET IN NEURONAL INJURY 
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4.1 Introduction 
Treatment of mouse cortical neurons with rotenone, followed by microarray analysis, 
identified a vast number of genes that were differentially expressed. The genes were 
categorized into nine biological processes using DAVID and Pubmed searches, 
which provided meaningful and useful information (Chapter 3). However, it is still 
too overwhelming as there are 208 genes listed on Appendix A, especially if only 
one particular gene candidate is going to be the focus of the subsequent studies.  
The aim of this chapter is to pinpoint an interesting target that will be a 
universal potential therapeutic agent for neurodegenerative diseases. Based on the 
fact that neurodegenerative diseases display a number of cellular dysfunction such as 
ubiquitin-proteasomal system impairment and excitotoxicity, the identification of 
that potential agent was carried out by overlapping the expression profile of rotenone 
with the other two expression profiles from 1 μM lactacystin- and 200 μM NMDA-
treated cortical neurons done previously (Figure 4.1).  
 
 
 
Figure 4.1: Research plan for Chapter 4. Expression profiles of rotenone-, 
lactacystin-, NMDA-treated cortical neurons were overlapped. Since genes listed in 
Appendix A have at least ± 1.5 fold change in either 8, 15 or 24 h, differentially 
expressed genes with at least ± 1.5 fold change in any one time point across all 
treatments were selected and categorized by DAVID and Pubmed searches. Novel 
gene from the largest functional group will be targeted for downstream studies. 
 
 
By overlapping expression profiles of rotenone-, lactacystin- and NMDA-
treated cortical neurons, we have identified three affected biological processes that 
are commonly affected; oxidative stress, dysfunction of calcium signalling and 
inhibition of the autophagic-lysosomal pathway. Srxn1 is highly upregulated at the 
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gene expression level in all the treatments. These data provide many opportunities 
for therapeutic intervention in neurodegenerative conditions, where mitochondrial 
dysfunction, proteasomal inhibition and excitotoxicity are evident. 
 
4.2 Summary of lactacystin- and glutamate-induced neuronal death 
In addition to mitochondrial dysfunction, both excitotoxicity and proteasomal 
inhibition have also been linked to cellular toxicity and pathology observed in the 
brain during normal aging, neurodegenerative diseases such as PD and AD, as well 
as cerebral ischemia (Ding and Keller, 2001; Grune et al., 2004; Keller et al., 2000a, 
2000b).  Prior to carrying out the comparative microarray analysis, a PubMed search 
was performed in order to review the current understanding of the mechanisms of 
lactacystin- as well as glutamate-induced neuronal death. 
 
4.2.1 Mechanism of lactacystin-induced neuronal death 
Dysfunction of the UPS can arise from impairments in ubiquitination, substrate 
delivery to the proteasome or a loss of proteasome activity (McKinnon and Tabrizi, 
2004). Lactacystin is a Streptomyces metabolite and an irreversible and specific 
inhibitor of the mammalian 26S/20S proteasome (Fenteany and Schreiber, 1998). It 
has been used in experimental studies to elucidate the mechanism of UPS 
dysfunction in neuronal cell death (Cheung et al., 2004; Choy et al., 2011; Fenteany 
and Schreiber, 1998; Li et al., 2008). UPS inhibition by lactacystin was reported to 
cause the formation of protein aggregates and induced apoptotic cell death in various 
types of primary neurons and in neuronal cell lines (Cheung et al., 2004; Rideout et 
al., 2001; Yew et al., 2005). Protein aggregation further impaired the UPS (Bence et 
al., 2001). Apoptosis induced by lactacystin was accompanied by mitochondrial 
dysfunction (Perez-Alvarez et al., 2009), cytochrome c release, caspase-3 activation 
(Qiu et al., 2000; Yew et al., 2005), elevated p53 expression (Du et al., 2009), 
chromatin condensation (Jantas et al., 2011), and translocation of cathepsin D to the 
cytosol (Miura et al., 2010). The involvement of the cell death promoting kinase, c-
Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase 1/2 (ERK1/2) 
and calpain activation also was observed in lactacystin-induced apoptosis (Jantas et 
al., 2011). Proteasomal inhibition was also reported to mediate deleterious alterations 
in cell cycle regulation (Rideout et al., 2003) and inflammatory processes and 
triggered the cell death (Demasi and Davies, 2003; Rideout et al., 2003; Rockwell et 
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al., 2000; Yew et al., 2005). Following exposure to lactacystin, activated caspase-3 
proteolytically cleaves protein kinase C-δ (PKCδ), which in turn has a positive 
feedback role in amplification of the mitochondria-mediated apoptotic cascade (Sun 
et al., 2008). Apart from PKCδ, PTEN is also a substrate of activated caspase-3 in 
lactacystin-treated neurons (Cheung et al., 2004), Figure 4.2.   
 
 
 
 
Figure 4.2 A summary of the reported mechanism of lactacystin action. Inhibition of 
UPS by lactacystin causes aberrant cell cycle re-entry, ER stress, mitochondrial 
depolarization and autophagy via the activation of p53 and subsequently leads to 
neuronal cell death. (Taken from Yap et al., 2016) 
 
 
4.2.2 Mechanism of NMDA-mediated neuronal cell death 
Upon activation of NMDARs, Ca2+ influx from the extracellular space increases 
cytosolic Ca2+ concentration. This event leads to plasma membrane depolarization 
and voltage-gated Ca2+ channel (VGCC) activation (Choi et al., 1988), which results 
in a further cytosolic Ca2+ rise. The toxic Ca2+ triggers excitotoxicity via many 
pathways (Figure 4.3). Firstly, it causes the dysfunction of organelles such as 
mitochondria and ER. High level of cytosolic Ca2+ causes mitochondrial Ca2+ uptake 
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and overload, mitochondrial membrane depolarization, production of superoxide 
followed by oxidative stress, cytochrome c release and caspase activation (Brewer et 
al., 2007; Ruiz et al., 2014; Stanika et al., 2009; Starkov et al., 2004; Stout et al., 
1998). At the same time, cytosolic Ca2+ overload can deplete ER Ca2+ store through 
ryanodine (RyR) and inositol 1,4,5-trisphosphate (IP3R) receptors (Wang et al., 
2004a). There are two main pathways through which ER can induce apoptosis. The 
ER and mitochondria are physically and functionally linked and that these two 
organelles engage in apoptosis crosstalk followed by the mitochondrial-dependent 
toxicity pathway mentioned above. Once ER Ca2+ stores are depleted, the UPR is 
activated (Verkhratsky and Petersen, 2002), and if UPR is prolonged, the ER itself 
can induce cell death by activating CHOP, a major component of ER stress-induced 
apoptosis (Paschen and Mengesdorf, 2005).  
 
 
 
 
 
Figure 4.3 Activation of NMDAR triggers Ca2+ influx. Increased cytosolic Ca2+ 
concentration induces ER stress and mitochondrial depolarization leading to calcium 
release from the intracellular stores and disrupting Ca2+ homeostasis in the cytosol. 
The dysfunction of Ca2+ signalling induces oxidative stress, aberrant cell cycle re-
entry, inhibition of UPS and prolonged activation of ALP, and all of these factors 
contribute to neuronal cell death. (Taken from Yap et al., 2016) 
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Secondly, toxic Ca2+ can lead to the activation of Ca2+-dependent proteins such 
as calcineurin and calpain. The NMDAR is found to be in a complex with neuronal 
nitric oxide synthase (nNOS) by synaptic scaffolding protein, postsynaptic density-
95 (PSD-95). With Ca2+ influx, nNOS is activated by calcineurin-induced 
dephosphorylation and generates NO (Oyadomari and Mori, 2004). Together with 
superoxide, NO is converted to peroxynitrite in the mitochondria. Formation of NO 
and peroxynitrite leads to the nitration of proteins or other peroxynitrite reaction 
products and oxidative stress. Nitrosylated SHP-2 inhibits the ERK1/2 survival 
pathway (Rameau et al., 2003) and nitrosylated c-terminal Src kinase (c-Src) 
activates the NMDAR by phosphorylating the NMDAR 2A subunit (Shi et al., 2013). 
On the other hand, peroxynitrite causes DNA damage and PARP-1 activation (Tang 
et al., 2012) and subsequent translocation of AIF to the nucleus, where it induces 
nuclear condensation. Apart from nNOS, calcineurin also activates BAD by 
dephosphorylation (de Murcia et al., 1994). Dephosphorylated BAD translocates to 
mitochondria and binds to Bcl-XL to induce cytochrome c release and the 
subsequent caspase-3 apoptotic cascade (de Murcia et al., 1994). Calpain is another 
important player in excitotoxicity, cleaving p35 to p25, which can in turn activate 
cyclin-dependent kinase 5 (CDK5). CDK5-p25 complex phosphorylates Cdh1 and 
promotes the accumulation of cyclin B1 in the nuclei, which mediates apoptotic 
death (Springer et al., 2000). Likewise, Cdh1 can also stabilize 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) leading to increased glycolysis and 
reduced activity of the pentose-phosphate pathway. This metabolic alteration triggers 
oxidative stress and excitotoxicity (Maestre et al., 2008). A recent study also 
demonstrated that calpain-cleaved E2F1 may contribute to NMDAR-mediated 
neurotoxicity (Rodriguez-Rodriguez et al., 2012). In addition, group IIA secretory 
phospholipase A2 (sPLA2-IIA) is activated in the presence of Ca2+ and reactive 
oxygen and nitrogen species (RONS) and its activity induces mitochondrial 
superoxide production after NMDAR stimulation. Inhibition of sPLA2-IIA fully 
prevents NMDAR-mediated neuronal apoptotic death (Zyskind et al., 2015).  
Thirdly, Ca2+ overload also affects the proper function of cellular systems such as 
UPS (Zyskind et al., 2015), ALP (Caldeira et al., 2013; Chiricozzi et al., 2010) and 
the cell cycle (Sadasivan et al., 2010; Springer et al., 2000; Wang et al., 2014). The 
down-regulation of proteasome activity is observed after stimulation with NMDA, 
possibly due to the activation of cathepsin L as well as the decrease in ATP content 
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as a result of mitochondrial dysfunction (Zyskind et al., 2015). In addition to the 
changes in the activity of the proteasome, a previous work on gene expression 
profiling revealed that NMDA-treated cortical neurons upregulated cell cycle re-
entry genes such as cyclin B1 (Sadasivan et al., 2010). Consistent with this, NMDA 
treatment promotes cyclin B1 accumulation in nuclei of cortical neurons via 
CDK5/p25 pathway and apoptotic cell death by abnormal entry in S-phase (Chen et 
al., 2013; Springer et al., 2000). Likewise, cell cycle re-entry, which does not 
proceed beyond the S-phase, has also been reported in primary cultures of rat 
hippocampal neurons after NMDAR stimulation (Springer et al., 2000). This aberrant 
cell cycle re-entry is triggered via JNK pathway and subsequent cyclin D1 induction. 
Also, autophagy induction is also observed in NMDA-mediated excitotoxicity 
(Caldeira et al., 2014; Chiricozzi et al., 2010; Efthimiadi et al., 2012; Pérez-Carrión 
et al., 2012). However, it is still debatable whether induction of autophagy is lethal or 
neuroprotective (Nagley et al., 2010). 
 
 
 
4.3 Oxidative stress, calcium overload and inhibition of autophagy-lysosomal 
pathway as the common affected biological processes in rotenone, lactacystin 
and NMDA treatments 
In Figures 1.1, 4.2 and 4.3, oxidative stress, unregulated intracellular Ca2+ level and 
impaired ALP occur in neuronal injury mediated by proteasome inhibition, 
mitochondrial inhibition and excitotoxicity. Therefore, we analysed the expression 
profiles of genes regulating these three pathways in rotenone (Yap et al., 2013), 
lactacystin (Choy et al., 2011), and NMDA (Chen et al., 2013) treated cortical 
neurons. Collectively these agents have been appropriately selected as each has been 
implicated in the pathogenesis of numerous inflammatory and oxidative stress–
related neurological dysfunctions. In addition, they are well-documented agents of 
neurodegenerative models through recapitulation of various pathological or 
morphological characteristics of the disease state. Furthermore, only those genes that 
demonstrated at least ± 1.5 fold in at least one of the time points in each treatment 
will be considered in this comparative study, and the results have been summarised 
in Table 4.1.  
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Table 4.1 Selected enriched biological processes consisting of significantly regulated 
genes common to rotenone, lactacystin and NMDA-induced neuronal injury models. 
The genes presented in the table were chosen based on the criteria of having at least 
±1.5 fold transcriptional expression in a minimum of one time-point and passed 
statistical testing, one-way ANOVA, p <0.05 in each transcriptomic profile. 
Individual transcriptomic profiles were subjected to functional-gene ontology 
classification using the online bioinformatics database DAVID. Selected biological 
processes were generated through gene enrichment and statistically validated by 
gene-term enrichment score through modified Fisher’s exact test and Benjamini 
correction. Up (↑) and/or Down (↓) arrow after the gene symbol denotes the overall 
regulatory trend over a 24 h time-course (48 h for lactacystin) transcriptomic study 
for each model. 
Biological 
Processes 
Rotenone Lactacystin NMDA 
Response to 
oxidative 
stress 
Atf4,Atf5, Cebpb, 
Gclm, Hmox1, 
Mt2, Nfe2l2, 
Prdx6, Srxn1, 
Gstm1 
 
↑Gsta4 
Cebpb, Gclm, 
Hmox1, Nfe2l2, 
Prdx6, Srxn1, Gsta4 
 
Mt2 
 
↑↓ Atf4 
 
Atf5, Gstm1 
Cebpb, Gclm, 
Hmox1, Mt2, Nfe2l2,  
Prdx6, Srxn1, Gsta4, 
Gstm1 
 
Atf4, Atf5 
Calcium ion 
binding and 
homeostasis 
Anxa2, Anxa3, 
Anxa5, Atp1a2, 
S100a6  
 
Calb2, Pnck 
 
 
Anxa2, Anxa5 
 
Anxa3, 
S100a6,S100a13 
 
 Atp1a2, Calb2, 
Pnck 
Anxa2, Anxa3, 
Anxa5, Atp1a2, 
S100a6,S100a13  
 
Calb2, Pnck 
 
 
Autophagy 
lysosome 
pathway 
Asah1,Cd63, 
Cd164, Ctsb, Ctsc, 
Ctsd, Ctsz 
 
Apg4b, Apg16l, 
Map1lc3a 
Asah1,Cd63, 
Cd164, Ctsb, Ctsc, 
Ctsd, Ctsz 
 
↑↓Apg4b,Apg16l 
 
Map1lc3a 
Asah1,Cd63, Cd68, 
Cd164, Ctsb, Ctsc, 
Ctsz 
 
 
Apg4b, Apg16l, 
Map1lc3a 
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4.3.1 Calcium homeostasis 
All treatments disrupted calcium homeostasis in which Anxa2, Anxa3, Anxa5, 
S100a13, and S100a6 are up-regulated, while Calb2 and Pnck are down-regulated 
(Table 4.1). There is a direct correlation between calcium homeostasis and ALP: 
rotenone and NMDA treatments affect both categories at 15 h while lactacystin 
treatment affects both categories at 48 h.  
 
4.3.2 Oxidative stress induced response 
As mentioned in previous reports, rotenone, lactacystin and NMDA impose oxidative 
stress in cortical neurons. Upon oxidative stress, Nfe2l2 is activated and induces the 
gene expression of phase II detoxifying enzymes e.g. Hmox1 and Srxn1. Oxidation of 
ER protein can also turn on the UPR leading to the activation of Atf4 and Cebpb 
transcription factors. As shown in Table 4.1 (ref. Appendix B), all treatments activate 
the Nfe2l2 pathway. Among them, rotenone treatment has the greatest impact on 
their expression, and is followed by lactacystin and NMDA. At 8 h of rotenone 
treatment, most of the genes are unaffected (fold-change ≤ 1.5). However, 11 genes 
(e.g. Atf4, Cebpb, Hmox1, and Srxn1) are up-regulated at 15h and the upregulation 
reaches its peak at 24 h. In the case of lactacystin, the changes of expression are 
detected as early as 4.5 h. The fold-change of those genes (Gclm, Hmox1, Srxn1) 
continues to increase and reaches its peak at 24 h. NMDA treatment, however, 
induces less drastic change on genes expression than rotenone and lactacystin with 
3.1 as the highest fold-change at 15 h. The change is detected as early as 5 h and 
reaches its peak at 15 h.  
 
4.3.3 Autophagy-lysosomal pathway 
The players of ALP can be classified into autophagic and lysosomal components. 
Obviously all the genes involved in autophagy such as Apg4b, Apg16l, and 
Map1lc3a are down-regulated by rotenone (15 h), lactacystin (24 h), and NMDA (15 
h) treatments. On the other hand, lysosomal genes, Ctsb, Ctsc and Ctsz, are up-
regulated by rotenone (15 h), lactacystin (4.5 h), and NMDA (5 h) treatments 
(Appendix B). These data suggest inhibition of autophagy and enhancement of 
lysosomal biogenesis.  
 
56 
 
4.4 Intersection between oxidative stress, aberrant calcium homeostasis and 
impaired ALP in neuronal PCD 
The comparative expression profiling suggested that oxidative stress, aberrant Ca2+ 
homeostasis and impaired ALP are critical to neuronal cell death. There is growing 
evidence indicating that dysfunction of ALP is a key event in neurodegeneration, 
thus it will be interesting to highlight some genes involved in ALP regulation. 
 
4.4.1 Oxidative stress and calcium homeostasis 
ROS are considered the most important oxidant molecules in cells. The largest 
amounts of ROS are produced in mitochondria through the electron transport chain 
(ETC) via the leakage of electrons that react with free oxygen in the matrix, 
producing superoxide. At the same time, Ca2+ modulates the ETC and ATP 
production by its activity on dehydrogenases of the tricarboxylic acid cycle and ATP 
synthase complex activation, in addition to its importance in maintaining the 
mitochondrial membrane potential (Llorente-Folch et al., 2015). Therefore, an 
imbalance in Ca2+ homeostasis can be an additional factor for cellular demise 
because it is mandatory for mitochondrial enzymes. There are extensive data linking 
alterations in Ca2+ homeostasis, mitochondria and apoptosis. In particular, in the 
CNS, excessive Glu in synaptic terminals can lead to Ca2+ overload via the over-
activation of iontropic NMDARs and subsequent excitotoxicity. This phenomenon 
can contribute to cell death during neurodegenerative processes. Mitochondria are 
particularly involved in the excitotoxicity process. Calcium is taken up by 
mitochondria through a uniporter (Santo-Domingo and Demaurex, 2010). This 
electrogenic channel has a low affinity for calcium and forms “microdomains” of 
Ca2+ within the ER, which releases Ca2+ through IP3R and RyR. The massive Ca2+ 
increase evoked by Glu can cause mitochondrial calcium overload. Calcium 
accumulation in the mitochondria drives unregulated bioenergetics, which in turn can 
generate more ROS and eventually open the permeability transition pore, reducing 
cell viability and ultimately leading to cell death (Santo-Domingo and Demaurex, 
2010).  
During proteasome inhibition, particularly in postmitotic cells like neurons, 
there is an accumulation of insoluble particles, which might aggregate in 
autophagosomes and hamper the autophagic system. Because the autophagic system 
is impaired, damaged mitochondria produce a large amount of ROS that cannot be 
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recycled. A reduction in mitophagy (mitochondrial autophagy) may also be involved 
in ageing-related diseases, such as PD. In this process, the protein aggregation of 
filamentous intracytoplasmic inclusions called Lewy bodies cannot be removed by 
autophagy. Approximately 5% of PD cases are caused by genetic changes that lead 
to alterations in the expression of such proteins as PTEN-induced putative kinase 1 
(PINK1) and parkin, which are related to mitophagy. When mitochondria are 
damaged, PINK1 accumulates in the outer mitochondrial membrane (OMM) for the 
recruitment of parkin and subsequent mitochondrial degradation, and one of the most 
common stimuli used to sensitize the PINK1-parkin system is the dissipation of 
membrane potential (Tanaka and Matsuda, 2014). Taken together, the intersection 
between oxidative stress, calcium and autophagy should be clarified with regard to 
molecular alterations in the neuronal death process.  
 
4.4.2 Interactions between oxidative stress and ALP 
In the CNS, autophagic imbalance is seen in various chronic neurodegenerative 
diseases, including PD (Xilouri et al., 2009), AD (Boland et al., 2008), cerebral 
ischemia (Wen et al., 2008), ALS (Nah et al., 2015). Moreover, Gene Wide 
Association Studies are now revealing disrupted ALP signaling in conditions such as 
frontotemporal dementia where two proteins involved in lysosomal biology have 
been implicated in its pathology (Ferrari et al., 2014), supporting earlier evidence of 
dysfunctional autophagy (Brady et al., 2013; Hu et al., 2010) . However, what is 
exactly causing the autophagic imbalance remains unknown. Oxidative stress and 
cellular accumulation of ROS are proposed as the causative agents of autophagic 
imbalance under pathological conditions. Rotenone is a potent mitochondrial 
complex I inhibitor and is used to induce oxidative stress (Janda et al., 2012). Also, 
rotenone induces cytoplasmic inclusions as observed both in in vivo (Betarbet et al., 
2000) and in vitro (Diaz-Corrales et al., 2005) studies, which may implicate a 
possible defect in protein turnover and autophagy. Rotenone does not seem to 
positively regulate autophagy (Janda et al., 2012) as (1) it does not induce 
autophagosome in neurons, astrocytes and neuronal cell lines, but it potently induces 
autophagic cell death in transformed and cancer cells HEK293 and HeLa cells; (2) 
prolonged exposure to nonlethal doses of rotenone strongly decreased autophagy 
levels possibly by reducing cell metabolism in this cell system; (3) autophagy 
inducers (rapamycin, valproic acid, lithium) provide significant protection against 
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rotenone-induced apoptosis. This evidence is in line with our microarray data that 
genes related to early steps in autophagy, such as Map1lc3a, are downregulated.  
As mentioned previously, mitochondria, which can take up large cytosolic 
Ca2+ loads, have long been considered to be critical targets of NMDA-induced 
neuronal injury. NMDAR-mediated Ca2+ increases cause oxidative stress via the 
release of ROS from the mitochondria into the cytosol (Dugan et al., 1995; Reynolds 
and Hastings, 1995) and the activation of NADPH oxidase (Brennan et al., 2009), as 
well as NOS (Sattler et al., 1999). Likewise, inhibition of proteasome activity 
sensitizes neurons to oxidative stress (Mytilineou et al., 2004) and rapamycin 
protects against lactacystin-induced neurodegeneration (Pan et al., 2008). 
The redox regulation of autophagy may occur on different targets: upstream 
signal transducers, transcriptional factors, direct regulatory proteins interacting with 
autophagy machinery, and at the level of autophagy machinery, including lysosome 
degradative enzymes and lysosomal membrane (Janda et al., 2012). Amongst the 
oxidative stress induced genes (see Appendix B), Atf4 (B’chir et al., 2013), Cebpb 
(Abreu and Sealy, 2012), Hmox1 (Lin et al., 2014; Zhao et al., 2014), Gsta4 (Liang 
et al., 2012) and Mt2 (Baird et al., 2006) have been reported to affect ALP. Atf4 is a 
transcription factor activated by oxidative stress-mediated UPR that induces the 
expression of Map1lc3b (B’chir et al., 2013), an important effector of autophagy. For 
instance, Hmox1, which is highly inducible in response to oxidative stress, is 
beneficial in preventing cardiac dysfunction by reducing cardiac oxidative stress, 
inflammation and apoptosis and enhancing cardiac autophagy (Zhao et al., 2014). 
Lin and co-workers (2014) also showed that upregulation of Hmox1 can prevent 
rotenone-induced dopaminergic cell death by regulating autophagic flux. High levels 
of one of the Cebpb isoforms leads to the induction of autophagy and cell death in 
breast cancer cell lines (Abreu and Sealy, 2012). Mt2 can stabilize lysosomes by 
chelating redox-active ferrous form iron and preventing intralysosomal Fenton-type 
reactions. Nfe2l2 a pivotal transcription factor in the defence against oxidative stress 
strongly induces expression of an autophagy adaptor protein NDP52 (Jo et al., 2014). 
 
4.4.3 Calcium homeostasis and ALP 
The role for Ca2+ in autophagy was first reported in rat hepatocytes, where a decrease 
as well as an increase in cytosolic Ca2+ levels inhibited autophagy (Gordon et al., 
1993). Recent findings identified intracellular Ca2+ as a key regulator of both basal 
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(Cárdenas et al., 2010) and induced (Hansen et al., 2007) autophagy. In addition, 
autophagy has been shown to be dependent on the calcium-dependent activation of 
AMP-activated protein kinase (AMPK) (Høyer-Hansen and Jäättelä, 2007). Also, an 
increase of cytoplasmic calcium seems to be necessary for lysosome-lysosome fusion 
(Bakker et al., 1997), lysosome-phagosome fusion (McCormack et al., 1990), and 
lysosome-plasma membrane fusion (Rodríguez et al., 1997). However, it is worth 
noting that rises in cytosolic Ca2+ affect cells in a different way. Cytosolic Ca2+ 
induces autophagy in non-excitable cells while it inhibits autophagy in excitable cells 
such as neuron (Ghislat and Knecht, 2013). This effect is mainly due to the activation 
of calpains that cleave proteins essential for autophagy i.e. Atg5. Furthermore, the 
presence of different Ca2+-sensor proteins in both groups of cells activate distinct 
signalling routes which can also contribute to the opposite autophagic responses. 
Therefore, this scenario might explain why autophagy-related genes such as Apg4b, 
Apg16l and Map1lc3a are downregulated in neurons treated with rotenone, 
lactacystin, and NMDA (Table 4.1).  Also, several neuroprotective agents such as 
amurensin G (Ryu et al., 2013), celastrol (Deng et al., 2013), DJ-1 (Gao et al., 2012), 
kaempferol (Filomeni et al., 2012) rapamycin (Giordano et al., 2014), trehalose (Wu 
et al., 2015), and valproic acid (Xiong et al., 2011) attenuated rotenone-induced 
injury through enhancement or induction of autophagy. Likewise, it is also 
undeniable that induction of autophagy is protective against proteasomal inhibition 
and NMDA-induced neurotoxicity (Du et al., 2009; Pan et al., 2008; Pérez-Carrión et 
al., 2012).  
With the notion that impairment of ALP is detrimental, it will be interesting if 
Ca2+-dependent proteins that affect ALP can be identified. In our studies, Anxa2 and 
Anxa5 are up-regulated while Calb2 and Pnck are down-regulated in rotenone, 
lactacystin and NMDA treatments (Table 4.1). Among them only Anxa2 and Anxa5 
have been associated with autophagy, whereby Anxa2 mediates the fusion of early 
endosome (Emans et al., 1993) while Anxa5 is involved in the formation of 
autophagolysosomes (Ghislat et al., 2012).  
 The convergence of the gene expression profiling of rotenone, lactacystin and 
NMDA-induced neuronal cell death propose that mitochondrial inhibition, UPS 
inhibition and NMDAR over-activation provoke oxidative stress and aberrant Ca2+ 
homeostasis as mitochondria and ER are physically and functionally linked. Together 
these events lead to downstream inhibition of autophagy (Figure 4.4). Oxidative 
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stress, aberrant Ca2+ and impaired ALP are interconnected and the activation of 
autophagy is believed to be pro-survival. Indeed, more generally targets in the ALP 
cascade have potential for the management of brain pathologies (Friedman et al., 
2015).  
 
 
 
 
Figure 4.4: Interconnection of biological processes during neuronal cell death. 
(Taken from Yap et al., 2016) 
 
 
4.5 Conclusion: Srxn1, a potential therapeutic target for neurodegeneration 
It is seemingly that oxidative stress induced response might be the most important as 
it constituted the largest affected group. Among the genes involved in defence 
against oxidative stress via the Nrf2 pathway, our attention was drawn to Srxn1. 
What makes Srxn1 so special is its specific sulfinic acid reductase and denitrosylase 
activities to redox regulatory Prxs. Prxs have been reported to be overexpressed 
and/or aberrantly expressed in several neurodegenerating disorders, including AD, 
PD, and others associated with progressive aggregate formation (Davey and Bolanos, 
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2013; De Simoni et al., 2008; Hu et al., 2011). The regulation of Prx activity by 
acetylation (Parmigiani et al., 2008), phosphorylation (Qu et al., 2007), 
hyperoxidation and S-nitrosylation (Fang et al., 2007) can affect neuronal survival. 
Furthermore, mRNA of Srxn1 as a regulator of Prxs was found to be upregulated in 
neuronal injury models induced by excitotoxicity (2-amino-3-(3-hydroxy-5-methyl-
isoxazol-4-yl)propanoic acid (AMPA), kainic acid (KA), NMDA and L-glutamate) 
(Chen et al., 2013), proteasome inhibitor (lactacystin) and mitochondria dysfunction 
(rotenone). In agreement with this, the activation of the synaptic NMDAR leads to 
upregulation of Srxn1 mRNA expression (Papadia et al., 2008) and also the 
proteasome inhibitor MG132 was reported to trigger AP-1 signaling and 
subsequently activate Srxn1 in Neuro2A cells (Nagashima et al., 2011). Also, several 
studies have shown that the molecular targets of Srxn1, Prxs, are linked to PD. The 
above observations suggested that manipulating Srxn1 expression or its activity, in 
turn, the redox activities of the 2-Cys Prxs, have an important potential in therapeutic 
strategies for neurodegenerative diseases. 
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CHAPTER 5 
ESTABLISHING AN IN VITRO MODEL FOR THE 
STUDY OF THE NEUROPROTECTIVE EFFECT OF 
SRXN1 
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5.1 Introduction 
Since the discovery of Srxn1 as a sulfinic acid reductase of 2-cys Prx in 2003, 
pharmacological compounds to specifically enhance the protein expression level of 
Srxn1 in cells have not been reported, however a few chemicals have been identified 
as inhibitors of Srxn1 activity (Kim et al., 2009, 2016). All the studies use 
overexpression or gene silencing methods to study the protective role of Srxn1 as 
summarized in Table 1.3. In order to demonstrate the ability of Srxn1 to attenuate 
rotenone-mediated neuronal death (Aim 3), the gene expression of Srxn1 will thus be 
manipulated.  
As mentioned in Section 1.6.2, Srxn1 has different protein expression level in 
different tissues and it is not expressed in some cell types, for example, Srxn1 is not 
detected in cells derived from normal colon epithelium (NCM460) or cells derived 
from well-differentiated colorectal carcinomas (SW640 and HT29) but it is highly 
expressed in poorly differentiated, aggressive HCT116 cells (Jiang et al., 2015). The 
research plan for this chapter is outlined in Figure 5.1. Srxn1 expression will be 
detected in control and rotenone-treated cells by immunoblot and this will determine 
the gene manipulation approach to be chosen to study the ability of Srxn1 to 
attenuate rotenone-mediated neuronal cell death. .  
 
 
Figure 5.1: A flow-chart showing the experimental steps carried out in this chapter. 
Srxn1 will be detected in untreated and rotenone-treated neurons. The absence or 
presence of Srxn1 will determine the overexpression or knock-down of Srxn1 in 
neurons.  
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5.2 Preparation of recombinant mouse Srxn1 
Since Srxn1 expression has never been reported in mouse cortical neurons, two 
commercially available Srxn1 antibodies were tested to validate their sensitivity for 
subsequent use in this study. First, a C-terminal His-tagged mouse Srxn1 (His-
mSrxn1) fusion protein was prepared as described in Section 2.7. Eluates were 
separated using 15% SDS-PAGE and the protein purity was ascertained by 
Coomassie Blue staining. Figure 5.2 shows a preparation of purified His-mSrxn1 
fusion protein at the expected molecular weight of ~15 kDa.  
 
 
 
 
Figure 5.2: Coomassie blue staining of purified His-mSrxn1fusion protein.  
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5.3 Evaluation of the sensitivity of Srxn1 antibodies 
The purified recombinant protein was used for western blotting to validate the two 
commercially available antibodies, Proteintech polyclonal Srxn1 antibody and the 
Santa Cruz monoclonal Srxn1 antibody (Figure 5.3). Through a series of dilutions of 
recombinant Srxn1, we showed that both antibodies are sensitive and suitable for 
detection of Srxn1 by western blot.  
 
Figure 5.3: Evaluation of the sensitivity of Srxn1 antibodies. Purified Srxn1 protein 
was quantitated and diluted with elution buffer to the indicated amount. Diluted 
Srxn1 protein was run on a 15% SDS-PAGE and incubated with two different Srxn1 
antibodies.  
 
 
5.4 Srxn1 protein expression was not detected in rotenone-treated cortical 
neurons  
Rotenone-mediated programmed cell death (PCD) was demonstrated by a dose-
dependent increase of active caspase-3 after 24 h treatment (Figure 5.4). Treatments 
with MG132 and staurosporin (STA) were used as positive controls for the detection 
active caspase-3. Subsequently, the protein expression of Srxn1 was assessed in 
neuronal cells treated with rotenone by immunoblot assay. Srxn1 was not detected in 
the untreated control as well as in cells treated with increasing concentrations of 
rotenone (Figure 5.4). It is possible that rotenone-mediated apoptosis triggers an 
increase of Srxn1 expression at the mRNA level but not at the protein level. The 
expression of Srxn1 in treated neurons was further investigated by immunostaining 
and confocal microscopy (Figure 5.5). The result revealed that Srxn1 protein was 
only detected in a minority of treated neurons and it localized mainly in the cytosol 
and perinuclear regions. 
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Figure 5.4: Srxn1 expression in cortical neurons treated with rotenone. Mouse 
cortical neurons were treated with rotenone, proteasome inhibitor (MG132) and 
staurosporin (STA) for 24 h. Cell lysates (50 µg of protein) were resolved on a 15% 
gel with purified His-mSrxn1 fusion protein (10 ng) as a positive control. The 
membrane was subjected to immunoblot analysis with antibodies specific for active 
caspase-3, Srxn1 and β-actin (loading control). 
 
 
 
 
 
 
Figure 5.5: Representative imaging of immunostaining of Srxn1 in rotenone-treated 
neurons. Cortical neurons were treated with vehicle control or rotenone for 24 h. 
Then, the neurons were fixed and immunostained with Srxn1 antibody and viewed 
under confocal microscopy. Scale bar = 8 μm. 
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5.5 Overexpresion of Srxn1 in neuron 
As outlined in Figure 5.1, absence of Srxn1 protein expression in untreated and 
rotenone-treated neurons, indicates the need for overexpression of Srxn1 in neurons. 
However, the overexpression of an antioxidant might be toxic to the cells while the 
redox balance is critical for cell survival (Trachootham et al., 2008), thus, it is 
beneficial to have an inducible expression system that can turn on Srxn1 expression 
only when needed.  
 
5.5.1 Background of the Tet-On inducible system   
Two vectors are required for the Tet-On inducible system: the regulatory vector 
(pLVX-Tet-On Advanced) and the response vector (pLVX-Tight-Puro) (Figure 5.6). 
The regulatory vector constitutively expresses a tetracycline-controlled transactivator, 
rtTA-advanced (Urlinger et al., 2000). On the other hand, the gene of interest (GOI) 
is inserted into the response vector and the gene expression is induced upon binding 
of rtTA-advanced to the promotor region. In the absence of doxycycline (Dox), 
rtTA-advanced can not bind to the promotor region of pLVX-Tight-Puro, thus there 
is no gene expression. In the presence of Dox, rtTA-advanced binds to the promotor 
region and thereby triggers the expression of GOI. 
 
5.5.2 Transient transfection of Tet-On inducible Srxn1-eGFP in mouse cortical 
neurons 
It has been reported that when lipid-mediated transfection was used to transfect 
postmitotic neurons, transfection efficiencies were poor, typically 1 - 5% (Karra and 
Dahm, 2010). Given the availability of, pLVX-Tight-Puro-mSrxn1-eGFP plasmid 
and as proof of concept it was transiently co-transfected with pLVX-Tet-On 
Advanced plasmid into cortical neurons followed by induction with Dox and the 
Srxn1-eGFP signal was captured by fluorescence microscopy to estimate the 
transfection efficiency based on green fluorescence. The images show that only 2% 
of the population expressing mSrxn1-eGFP (Figure 5.7). Therefore, from the above 
data it can be concluded that mouse cortical neurons are not suitable model for this 
study. 
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Figure 5.6: The components of the Tet-On inducible system: the regulatory vector 
and the response vector. The transactivator, rtTA-advanced, is constitutively 
expressed by the regulatory vector. It can only bind to the promoter region of the 
response vector and induce the expression of target gene in the presence of Dox.  
 
 
 
 
Figure 5.7. Representative images of cortical neurons transfected with Srxn1-eGFP. 
Scale bar = 80 μm. 
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5.6 Generation of three tetracycline-inducible (Tet-On) Flag-hSrxn1-eGFP, 
Flag-hSrxn1 and hSrxn1-Flag SH-SY5Y stable cell lines by a 2-step transfection 
procedure 
Due to the low transfection efficiency of cortical neurons with Lipofectamin (Section 
5.5), all the subsequent studies were carried out using the human neuroblastoma SH-
SY5Y cell line, as rotenone-treated SH-SY5Y is a well-established in vitro model of 
Parkinson’s disease (PD). Given the high cost for the transfection reagents, the 
generation of a stably-transfected neuronal cell line that allows long-term, as well as 
defined and reproducible, expression of Srxn1 is thereby more economical for all the 
subsequent studies of Srxn1 neuroprotection.  
 
5.6.1 Stable transfection of SH-SY5Y with pLVX-Tet-On Advanced 
The Tet-On inducible Srxn1 expression system was first produced by stably 
transfecting SH-SY5Y cells with the regulatory vector, pLVX-Tet-On Advanced, 
from now on referred to as Tet-On Advanced SH-SY5Y cells. After transfection, 
antibiotic selection was performed on the transfected cells to eliminate the 
untransfected cells. This resulted in a more homogenous (but still polyclonal) cell 
population. The polyclonal cell line was then transiently transfected with pLVX-
Tight-Puro-eGFP vector and viewed under microscopy for green fluorescence to 
validate the stable insertion of the regulatory component. 
 
5.6.2 Stable transfection of Tet-On Advanced SH-SY5Y with three types of human 
Srxn1 constructs 
Three different constructs of Flag-tagged Srxn1: Flag-hSrxn1-eGFP, Flag-hSrxn1 
and hSrxn1-Flag (Figure 5.8) were transfected into the Tet-On Advanced SH-SY5Y. 
After transfection, antibiotic selection and induction, the Srxn1 expression level in 
three different Tet-On inducible Srxn1 SH-SY5Y cell lines was examined by western 
blot and immunostaining (Figure 5.9). The expression of Srxn1 fusion proteins were 
under tight regulation as there was no expression of Srxn1 fusion proteins in the 
absence of Dox (Figure 5.9A). To detect the Srxn1 protein in the cells, western blot 
analyses were carried out using anti-Flag antibody for Flag-tagged Srxn1 while anti-
Srxn1 antibody for both flag-tagged and endogenous Srxn1 (Figure 5.9A). As shown 
by Figure 5.9A, strong bands corresponding to the 41 kDa of the intact Flag-hSrxn1-
eGFP and 14 kDa of the Flag-Srxn1 were detected by both antibodies. An extra band 
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of approximate 25 kDa with unknown nature can be observed for Flag-hSrxn1-eGFP 
with the anti-Srxn1 antibody. Interestinly, no signal was detected for the Srxn1-Flag 
cell lysate induced by Dox with either the anti-Srxn1 or anti-Flag antibodies (Figure 
5.9A). These findings were further confirmed by immunostaining where only Flag-
hSrxn1 was successfully expressed in the cells upon the addition of Dox (Figure 
5.9B). Therefore, Flag-hSrxn1 was selected for downstream experiments. 
 
 
 
 
 
 
 
 
Figure 5.8: A simplified diagram of the generation of double-stable Tet-On 
inducible Flag-hSrxn1-eGFP, Flag-hSrxn1 and hSrxn1-Flag SH-SY5Y. 
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Figure 5.9: Determination of Srxn1 fusion proteins expression levels. A. Western 
blot analyses; B. Immunostaning. Scale bar = 80 μm. 
 
 
 
 
 
 
 
 
Figure 5.10: Representative images of Tet-On inducible Flag-hSrxn1 stained with 
Hoechst 33342, anti-Srxn1 antibody and anti-Flag antibody. Arrows indicate 
representative cells positive for Srxn1 expression after the images were merged. 
Scale bar = 80 μm. 
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5.7 Determination of Flag-hSrxn1-positive population in transfected SH-SY5Y 
Since the double-stably transfected cell line is polyclonal, the population of Srxn1-
expressing cells was determined. The immunostained images of Flag-hSrxn1 
transfected cells were subjected to cell counting manually. Before cell counting, 
images were taken for cells stained with H33342, anti-Flag and anti-Srxn1 antibodies 
and merged. The number of H33342 stained cells represented the total population 
and the number of anti-Flag and anti-Srxn1 represented the Srxn1-expressing cells 
(Figure 5.10). A total of 371 cells were counted and 168 cells were stained with both 
anti-Flag and anti-Srxn1, which corresponds to 45% of the population. 
 
 
5.8 Discussion and conclusion 
The microarray study has identified the potential neuroprotective role of Srxn1 in 
rotenone-mediated neuronal death. However, it was difficult to manipulate Srxn1 
expression levels in primary neuronal culture due to its low transfection efficiency. 
Furthermore, the study of proteins with low expression levels can be challenging 
since mature neurons do not undergo cell division and thus are unable to provide 
unlimited cell numbers. The preparation and culture the primary neurons in large 
quantity can be expensive and labour intensive. Therefore, there was a need to 
generate a sustainable and easy way to manipulate the expression of Srxn1 for the 
subsequent studies.   
In this chapter, an inducible SH-SY5Y stable cell line that allowed for the 
manipulation of Srxn1 gene expression was generated. SH-SY5Y is widely used as 
an in vitro model in PD research (Xicoy et al., 2017).  Advantages of using SH-
SY5Y include the capacity for large-scale expansion prior to differentiation, with 
relative ease and relatively low cost to culture. Also, SH-SY5Y are human-derived, 
they express a number of human-specific proteins and protein isoforms that would 
not be present in rodent primary cultures (Kovalevich and Langford, 2013). In 
addition, SH-SY5Y also has the ability to reproduce the cellular abnormalities of PD 
such as α-synuclein aggregation, abnormal mitochondrial function, oxidative stress 
and autophagy or proteasomal dysfunction (Xicoy et al., 2017). However, there are 
also drawbacks of using SH-SY5Y cell line in PD research. SH-SY5Y was shown to 
have only negligible levels of tyrosine hydroxylase activity (Ross and Biedler, 1985), 
which is the rate-limiting enzyme of dopamine synthesis pathway. Therefore, the use 
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of an oncogenically transformed cell line without an exclusively dopaminergic 
properties remains a controversial issue in the PD field (Xicoy et al., 2017). In any 
case, the use of other models (such as primary cultures of dopaminergic neurons) in 
parallel is recommended and gene modification in primary neuronal cultures can be 
facilitated by CRISPR/Cas9 (Xicoy et al., 2017). 
 Overall, a stably transfected cell line has more advantages as compared to a 
transiently transfected cell line for the study of gene function. Differentiated cells 
especially differentiated neurons present a particular challenge regarding the 
efficiencies for introducing and expressing exogenous constructs. Also, 
differentiation protocols require the cells to be cultured in vitro for a longer duration, 
so there is a tendency for the loss of gene expression if the gene is not incorporated 
into the genome. However, one can easily expand a non-differentiated stable line and 
differentiate it at its convenience. Such a stable cell line is also more cost-efficient 
compared to transient transfection.  
Another important aspect of the work documented in this chapter is the 
development of a simple and rapid protocol of inducible system to drive Srxn1 
expression. Gene manipulation approach is often challenged by the intrinsic 
properties of the studied gene. For instance, genes that would be lethal or 
compromise cellular adhesion, possibly leading to anoikis, cannot be overexpressed 
constitutively without affecting subculturing of the cells. Inducible overexpression 
system allows the investigation of genes that would be lethal or otherwise poorly 
tolerated if constitutively expressed to be made possible. Furthermore, inducible 
system minimizes the complications caused by the activation of compensatory 
mechanism as a result of long-term continuous gene overexpression during result 
interpretation (Georgievska et al., 2004). In addition, Tet-On inducible systems offer 
other advantages such as more thorough investigations into the specific timing of 
gene function, the overexpression of gene is reversible, dose-response studies over a 
wide range of expression levels are feasible. The effect exerted by the inducible 
constructs can be controlled by the concentration of Dox (1-10 μg/ml) (Kappel et al., 
2007).  
  Using the method describes in Section 2.13 and 5.6, two different types of 
stable SH-SY5Y cell lines have been generated: a SH-SY5Y Tet-On regulator stable 
cell line and an inducible SH-SY5Y Flag-Srxn1 stable cell line. Both lines can be 
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considered as powerful tools for the study of neurological diseases as the use of the 
SH-SY5Y cell line is not restricted to PD-research (Xicoy et al., 2017). The stable 
SH-SY5Y Tet-On regulator line is ready for both transient and stable transfection of 
other genes-of-interest involved in neurodegeneration. It serves as a very good 
starting point for numerous research projects. On the other hand, the inducible SH-
SY5Y Flag-Srxn1 would be particularly useful for the study of Srxn1 function in a 
spatiotemporal fashion. Besides, the inducible SH-SY5Y Srxn1 stable cell can be 
further transfected with differently tagged transgenes to allow a plethora of 
experiments studying the relationship between two genes.  
There are some considerations in the research plan when using these two 
stable lines for the study. Since these two lines are not monoclonal stable lines, the 
cell population is highly heterogeneous. Techniques use population average readouts 
at single time points such as MTT assay, lactate dehydrogenase release and western 
blot might mask the effect genes and are at a disadvantage for studying cell types 
with low transfection efficiency. Analysis of the protective mechanisms of Srxn1 
will require additional techniques, such as immunostaining and flow-cytometry for 
single-cell analysis. 
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CHAPTER 6 
OVER-EXPRESSION OF SULFIREDOXIN IS 
PROTECTIVE TO NEURONS EXPOSED TO LOW 
LEVELS OF ROTENONE 
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6.1 Introduction  
After successfully establishing a SH-SY5Y Tet-On inducible Flag-Srxn1 stable cell 
line, the neuroprotection of Srxn1 on rotenone-induced neuronal injury is examined 
in this chapter. Table 6.1 provides some examples of rotenone-treated SH-SY5Y 
Parkinson’s disease (PD) models used in the PD research. Although PD is a 
neurodegenerative disease characterized by progressive loss of dopaminergic 
neurons in the substantia nigra par compacta for over decades, most of the studies 
outlined in Table 6.1 used non-differentiated neurons, acute concentration of 
rotenone that do not closely mimic the chronic condition of PD.  It is worth noting 
that Borland and co-workers (2008) managed to use a chronic and low-dose rotenone 
to slowly kill the specially differentiated SH-SY5Y over a course of 21 days.  
The primary scope of this chapter is thus to develop an in vitro PD model that 
would closely mimic the PD condition. Flag-Srxn1 SH-SY5Y was differentiated with 
retinoic acid (RA) and brain-derived neutrophic factor (BDNF) and followed by the 
identification of the optimum dose of rotenone that slowly induce PCD over a period 
of time. After obtaining an experimental setting mimicking PD, the neuroprotection 
of Srxn1 is studied by the addition of Dox (Figure 6.1).  
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Table 6.1: Some examples of rotenone-induced SH-SY5Y in vitro PD models. 
SH-SY5Y Concentration 
used 
Treatment 
duration 
References 
Non-differentiated 10 μM 24 h Park and Kim, 2013 
Non-differentiated 5 nM 4 weeks Shaikh and Nicholson, 2008 
Non-differentiated 2.5-20 μM 24 h Horst et al., 2017 
Non-differentiated 1 μM 24 h Martin et al., 2016 
Non-differentiated 4 μM 48 h Zhang et al., 2017 
Non-differentiated 0.5 μM 24 h Rcom-H'cheo-Gauthier et al., 
2017 
Non-differentiated 2 μM 24 h Zhao et al., 2017 
Differentiated 0.5 μM 48 h Van Laar et al., 2016 
Differentiated 0.2 μM 24 h Nataraj et al., 2016 
Differentiated 10-100 nM 24 h Knaryan et al., 2014 
Differentiated 50 nM 21 days Borland et al., 2008 
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Figure 6.1: A simplified diagram showing the steps taken in this chapter to demonstrate the neuroprotective role of Srxn1 in rotenone-induced 
injury. Subacute rotenone concentration is first determine in differentiated Flag-Srxn1 SH-SY5Y. Srxn1 against rotenone neurotoxicity is 
demonstrated in the presence of Dox. 
79 
 
6.2 Rotenone induced neuronal injury in differentiated SH-SY5Y cells 
Stably transfected SH-SY5Y Flag-Srxn1 from Chapter 5 was differentiated with 
sequential treatment of RA and BDNF for 7 days prior to rotenone treatment (Section 
2.13). The study carried out in this Chapter was begun with treatment of 
differentiated Flag-Srxn1 SH-SY5Y with different concentrations of rotenone (0.1, 
0.5 and 1 μM) or vehicle control for 7 days duration. The injury caused by rotenone 
was assessed by both CCK-8 assay (Figure 6.2) and microscopic observation (Figure 
6.3).  
Rotenone caused a significant dose-dependent decrease in viability with 
~75% loss by 7 days as revealed by CCK-8 assay (Figure 6.2). Cells treated with 0.5 
and 1 μM rotenone had a similar response and they caused significant reduction of 
viability after 1 day of treatment. However, the viability of 0.1 μM rotenone-treated 
cells remained the same as the control after 1 day of treatment and only decreased 
after 4 days of treatment. Therefore, rotenone induced a chronic injury when the 
concentration is lower than 0.1 μM whilst it induced an acute injury with 
concentrations greater than 0.5 μM.  
It has been reported that rotenone inhibits axon formation in cultured 
hippocampal pyramidal neurons (Sanchez et al., 2008). The morphology of neurons 
were observed under phase contrast microscopy after rotenone treatment (Figure 6.3). 
The differentiated cells in vehicle control grew into a neuronal phenotype with 
neurites that continued to extend and form networks even after 7 days of vehicle 
treatment.  On the contrary, 0.5 and 1 μM rotenone greatly reduced the formation of 
neurite and also the cell bodies appeared swollen after 1 day of treatment. All the 
cells treated with 0.5 and 1 μM were rounded up after 7 days of treatment. However, 
cells treated with 0.1 μM rotenone only started to lose their neurite after day 4 and a 
complete disappear of neurite was observed after 7 days treatment with rotenone. In 
agreement with cell viability assay, 0.1 μM rotenone induced a chronic injury while 
0.5 and 1 μM rotenone caused acute injury to cells. In addition, the neurites of treated 
neurons exhibited marked swelling (Figure 6.4), which is one of the features of 
degeneration (Yang et al., 2013), beginning from day 1 of treatment while at this 
concentration, rotenone does not produce cell death as revealed by cell viability 
assay (Figure 6.2). This observation is in agreement with a previous report (Sanchez 
et al., 2008). Therefore, rotenone concentration of 0.1 μM was employed and 
treatment for 7 days was taken as end-point in all the subsequent studies. 
80 
 
 
 
 
 
 
 
 
 
 
  
Figure 6.2: The effect of rotenone on non-induced SH-SY5Y Flag-Srxn1 cell 
viability. Cells were treated with various concentrations of rotenone and incubated 
for 1, 4 and 7 days. Cell viability was determined by CCK-8 kit. Values are 
expressed as percentage of cell viability and SD. *p<0.05. 
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Figure 6.3: Representative images of on non-induced SH-SY5Y Flag-Srxn1 cell 
treated with indicated rotenone concentrations for 1, 4 and 7 days. Scale bar = 80 μm. 
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Figure 6.4: Neurite morphology in response to rotenone treatment. Representative 
images of cells treated with vehicle control and 0.1 μM rotenone for indicated time. 
Arrows indicate the swollen neurites. Scale bar = 30 μm. 
 
 
 
 
6.3 Srxn1-mediated protection of rotenone-treated differentiated SH-SY5Y 
Subsequently, Srxn1 protection against rotenone-induced injury was investigated in 
differentiated SH-SY5Y cells by inducing its expression with the addition of Dox (1 
μg/ml) together with the rotenone treatment. The CCK-8 cell viability assay showed 
that Srxn1 was significantly protective against injury induced by 0.1 μM rotenone 
(Figure 6.5A). Figure 6.5B shows that the neurite network was preserved in cells 
treated with rotenone for 7 days in the presence of Dox. 
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A                                                                
  
B 
  
Figure 6.5: The effect of Srxn1 against rotenone-induced neuronal injury. 
Differentiated SH-SY5Y Flag-Srxn1 were treated with rotenone (0.1 μM) for 7 days 
with or without the presence of 1 μg/ml doxycycline (Dox). A, Cell viability was 
measured using CCK-8 assay. Values are expressed as percentage of cell viability 
and SD. *p<0.05. B, Representative images of neurons treated with control or 
rotenone with or without the presence of Dox for 7 days. Scale bar = 80 μm. 
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Srxn1-mediated protection was further confirmed with western blot. Srxn1 
was highly overexpressed on day 4 and 7 in Dox-treated cells, where the Srxn1 bands 
were broad on the blot (ref. purified Srxn1 in Figure 5.4) Previous studies have 
shown that rotenone depolymerized tubulin due to mitochondrial dependent ATP 
depletion and ROS generation (Esteves et al., 2009; Ren and Feng, 2007). Hence, the 
integrity of cytoskeletal proteins, α-fodrin and tubulin, were examined. In accordance 
with the reduction of cell viability and loss of neurite following rotenone exposure 
(0.1 μM), the cytoskeleton proteins, α-fodrin and tubulin, were markedly reduced by 
rotenone after 7 days (Figure 6.6). However, the expression of α-fodrin and tubulin 
were preserved by overexpressing Srxn1. 
 
 
 
 
 
 
  
Figure 6.6: The neuroprotective effect of Srxn1. Differentiated SH-SY5Y Flag-
Srxn1 were treated with rotenone (0.1 μM) for 1, 4 and 7 days with or without the 
presence of Dox. Cell lysate were harvested and 50 μg protein was used for western 
blot for α-fodrin and Srxn1 detection.  
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In addition, rotenone causes nuclei condensation in the absence of Dox as 
shown in Figure 6.7. The number of condensed nuclei was reduced in the presence of 
Dox, which induced high expression of Srxn1 as demonstrated by immunostaining 
with anti-Srxn1 antibody (Figure 6.7). This further confirmed the protective effect of 
Srxn1 against rotenone treatment.   
 
 
 
 
  
 
Figure 6.7: Representative images of immunofluorenscence staining of differentiated 
SH-SY5Y FlagSrxn1 treated with vehicle control or rotenone with or without the 
presence of Dox for 7 days. Nuclei were stained with Hoechst 33342. Arrows 
indicate condensed nuclei. Scale bar = 80 μm. 
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6.4 Discussion and conclusion 
This study has successfully achieved the aims stated in Section 1.7. The combination 
of microarray technology and DAVID in Chapter 3 revealed that genes related to 
oxidative stress, UPS, ALS and calcium signaling were deregulated after rotenone 
treatment. The gene profiling study conducted in Chapter 4 identified Srxn1 as a 
potential protective agent against rotenone-induced neuronal injury. With the 
establishing of an in vitro PD model in Chapter 5, the neuroprotective effect of Srxn1 
in rotenone-mediated neuronal death has been clearly demonstrated in Chapter 6.  
Oxidative stress in PD was demonstrated in the substantia nigra of patients 
with PD and a decrease in the levels of the thiol antioxidant GSH is one of the 
earliest biochemical alterations detected in association with PD (Garcia-Garcia et al., 
2012). Likewise, the expression of genes related to GSH metabolism were altered in 
cortical neurons after rotenone treatment (see Chapter 3). Since GSH executes its 
redox functions by its thiol group, it would be of great interest to identify a thiol-
based redox signaling event that regulates neurodegeneration caused by rotenone.  
Oxidative stress is integrated into cellular signal transduction pathways 
mainly through the oxidation and reduction of cellular thiols. Since thiols readily 
react with almost all oxidants, a variety of oxidative cysteine modifications (sulfinic 
acid, sulfonic acid S-nitrosylation and glutathionylation) have been identified in PD 
(Garcia-Garcia et al., 2012). To date, a number of proteins such as DJ-1, Parkin, Prx 
I, Prx II, SOD1 are thiol modified in PD and experimental PD models (Garcia-Garcia 
et al., 2012).  
What will be the consequences of thiol modification? Many cellular 
processes can be modulated by thiol modification and it has been suggested that thiol 
redox state profoundly influence autophagy, especially during the phagophore 
elongation steps and autophagosome completion (Filomeni et al., 2010). An example 
of putative redox-sensing proteins implicated in autophagy is PTEN, which is a 
peculiar member of the huge class of protein tyrosine phosphatases (PTPs) (Filomeni 
et al., 2010). The catalytic Cys124 of PTEN undergoes reversible oxidation and 
forms disulfide bonds with its Cys71, which results in PTEN inactivation and 
autophagy inhibition (Filomeni et al., 2010). Prxs have been suggested to be able to 
antagonize the inhibitory effects of oxidative stress on PTEN. Therefore, Prxs might 
be implicated in the redox regulation of autophagy.     
87 
 
This study is of particular interest given that the gene expression of Srxn1, a 
regulator of thiol-based redox signaling, was found upregulated as revealed by 
microarray data (ref. Chapter 3). It is strongly believed that oxidative stress caused 
by rotenone triggers the activation of Nfe2l2 pathway, where the transcription factor 
Nrf2 translocates to nucleus and upregulates the gene expression of Srxn1 as a 
protective mechanism to reverse the oxidative stress (Figure 3.3). The hypothesis 
was further supported by immunocytochemical analysis of Nrf2 and Srxn1 in 
rotenone-treated neuronal cells derived from human induced pluripotent stem cells 
where Srxn1 protein increased in parallel with Nrf2 nuclear translocation after 
exposure to rotenone (Zagoura et al., 2016). Nrf2 activators (3H-1,2-dithiole-3-
thione and sulforaphane) have been shown to upregulated Srxn1 in both neurons and 
glia (Soriano et al., 2008). Also, induction of Srxn1 expression in response to H2O2 
or oxygen-glucose deprivation (OGD) in astrocytes was regulated by Nrf2 (Zhou et 
al., 2015). 
 Although Srxn1 was found highly upregulated at the gene expression level, 
its protein was not detected after exposure to rotenone both in mouse cortical neurons 
and SH-SY5Y cells. This observation can be explained by the possibility of 
deregulation protein translation control after rotenone exposure. Several reports have 
shown that proteins involved in protein translation processes such as EIF4G1 
(translation initiation factor) and LRRK2 (a regulator of the protein translational 
machinery) were mutated in PD (Taymans et al., 2015). A study combining 
transcriptomics and proteomics of substantia nigra, striatum and frontal cortex from 
both healthy and diseased brains showed a subset of protein abundance changes 
largely independent of mRNA changes (Riley et al., 2014; Taymans et al., 2015). 
Indeed, several translation initiation factor (Eif2c2, Eif2b1, Eif2b2, Eif2b4 and 
Eif2b5) have been found downregulated at gene level in cortical neurons after 
rotenone treatment (Appendix A). Downregulation of protein synthesis is particularly 
important under conditions predisposing to loss of mitochondrial quality control and 
mitochondrial dysfunction as suppression of protein translation helps to lower energy 
consumption. However, deregulation of protein synthesis can be neurodegenerative 
when pathogenic translational targets are upregulated while neuroprotective proteins 
are downregulated (Martin, 2016).  
 Overexpression of Srxn1 protein in differentiated SH-SY5Y cells 
successfully overcame deregulation protein translation control and prevented neurons 
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from rotenone-induced injury. As mentioned in Chapter 1, the enzymatic functions of 
Srxn1 are mostly related to 2-cys Prxs. Therefore, the protective mechanism of Srxn1 
might be related to its substrates functions and overexpression of Srxn1 could have a 
number of implications (Figure 6.8). I suggested that oxidative/nitrosative stress as 
an early event induced by rotenone (ref. Figure 3.3) leading to the formation of Prx-
SO2H and Prx-SNO, which by losing its peroxidase activity allows cytosolic ROS to 
rise even further. The resulting ROS activated Bax, causing caspase activation and 
cell death (Przedborski, 2007). Furthermore, a recent report showed that 
hyperoxidized Prx II was ubiquitinated and degraded by proteasome and autophagy 
(Song et al., 2016). Therefore, it is highly likely that the cellular pool of Prxs might 
be reduced when there is too much H2O2. Prxs are also believed to have a pro-
autophagic role as some of them (Prx I, Prx II and Prx VI) were found localized in 
the membrane of autophagosomes, where they maintain the putative redox-sensitive 
proteins eg. PTEN implicated in vesicle maturation and traffic and allow autophagy 
to proceed (Filomeni et al., 2010). The inactive Prxs (Prx-SO2H and Prx-SNO) might 
inhibit the onset of autophagy and the clearance of abnormal proteins, which is 
thought to be the mechanism for causing dystrophic neurite as shown in Figure 6.4 
(Yang et al., 2013). However, with overexpression of Srxn1, the hyperoxidized Prxs 
can be reduced and thus be rescued from degradation and the cellular Prxs pool can 
be restored. Also, the reduction of Prxs by Srxn1 can prevent the accumulation of 
ubiquitinated proteins as a result of the inhibition of proteasome and autophagy 
during oxidative stress.  
Apart from Prxs, Srxn1 also deglutathionylated actin and PTP1B. Upon 
oxidative stress, actin was found glutathionylated and actin polymerization inhibited, 
which could affect the structure of neurite (Coles and Bradke, 2015; Sakai et al., 
2012). Likewise, glutathionylation of PTP1B during oxidative stress inhibited its 
function causing axon retardation (Fuentes and Arregui, 2009; Li and Whorton, 
2003). Therefore, it is possible that Srxn1 preserved the neurites of rotenone-treated 
neurons by deglutathionylating actin and PTP1B.  
In conclusion, it is possible that Srxn1 overexpression rescued neurons from 
rotenone-induced injury by re-activating Prxs peroxide reductase activity, preventing 
degradation of cellular Prxs, inhibiting oxidative inactivation of the autophagic 
machinery and preserving neurite integrity (Figure 6.8). 
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Figure 6.8: Hypothesis on the possible redox implications of Srxn1 in rotenone-
mediated neuronal cell death.  
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Concluding Remarks 
 
Over the past 50 years, the treatment of PD has been optimized using 
pharmacotherapy, deep brain stimulation and physiotherapy. However, all treatments 
available until 2016 are of symptomatic nature and fail to slow down the progression 
of PD or even to prevent its manifestation. Therefore, knowledge on the processes 
leading to the pathogenesis of PD is important. The identification of targets that 
represent early stages of the disease is also critical and their treatment will result in 
adequate preservation of healthy neurons and neuronal networks.  
Rotenone has been used widely in neuroscience research to mimic the disease 
condition of PD. This neurotoxin has been shown to affect a number of biological 
processes as summarized in Figure 1.3. Most of the previous studies have focused 
only on a few of the proteins affected by rotenone. DNA microarray is a powerful, 
high-throughput tool for studying molecular mechanisms and it can examine the 
expression of thousands of genes simultaneously, giving an idea of gene expression 
in the cell at the time of the study. Based on the fact that the gene expression profile 
of a cell determines its function, phenotype and response to external stimuli, gene 
expression profiles can help to elucidate cellular functions, biochemical pathways 
and regulatory mechanism. This technology is very valuable in discovering several 
important targets for therapy that might not be practical to achieve by single-gene 
approaches. Chapter 3 presents the data obtained from the combination of microarray 
analysis on an in vitro rotenone neurodegeneration model and a statistical assessment 
of cellular processes changes using DAVID. This is a good example on how DNA 
microarray technology can be done to unveil biological processes associated with a 
pathological condition. 
Microarray analysis has been used in several studies of neuronal 
mitochondrial complex I inhibition profiling, in which the complex I inhibitor treated 
gene expression profile is compared with its corresponding control sample to 
measure the differences between both condition (Conn et al., 2003; Lee et al., 2003), 
and interesting targets has been identified but nevertheless these reports fail to 
provide temporal evaluation of the treatment. Other groups have investigated the 
temporal transcriptomic profile of marginal to moderately toxic cencentrations (5 and 
50 nM) of rotenone-treated undifferentiated human neuroblastoma, SK-N-MC cell 
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line, at 1 and 4 weeks (Cabeza-Arvelaiz and Schiestl, 2012; Greene et al., 2008). The 
altered mechanisms found in proliferating cells might not closely reflect the dying of 
postmitotic cells in the diseased brain. Furthermore, transcriptomic profile obtained 
after 1 and 4 weeks of treatment might fail to detect early immediate gene expression 
changes caused by rotenone. The work presented in Chapter 3 fills the gap by 
performing the temporal evaluation of rotenone treatment and detecting the 
immediate early gene expression patterns from three different time points (8, 15, and 
24 h). Among the nine affected biological processes identified in Chapter 3, 
dysfunction of the autophagy-lysosomal pathway (ALP) was not reported in a 
previous transcriptome analysis (Cabeza-Arvelaiz and Schiestl, 2012).  
Based on the fact that neurodegenerative diseases are very complex in nature 
and many biological processes might contribute to the dying of neuronal cells, the 
microarray data should not be analyzed independently. The comparison of 
transcriptome changes in rotenone, lactacystin and NMDA treated neurons identified 
shared components of the apoptotic or proliferation-control machinery during 
neuronal injury. The strategy of cross-pathway comparison described in Chapter 4 
lead to the identification of novel regulators such as Srxn1 and provides a global 
picture of shared regulatory events during apoptosis induction as described in Figure 
4.4, where dysfunction of ALP might be a commonly affected downstream biological 
process. The discovery of Srxn1 in the context of dysfunctional ALP may shed new 
light on its function.  
A major work presented in this thesis is the generation of a stable human 
neuroblastoma cell line with tetracycline-inducible flag tagged Srxn1 expression with 
the aim to reveal one or several of its function(s). While constitutively 
overexpression of the gene of interest might result in cell growth/proliferation defects 
or unwanted cell differentiation, Chapter 5 describes a two-consecutive step 
approach to efficiently generate a stable SH-SY5Y Tet-On cell line that reliably 
drives inducible Srxn1 overexpression. The ability to control gene expression by the 
highly specific Tet-On system offers the opportunity to study gene functions at 
different stages (for example during cell cycle progression or well-defined 
differentiation processes as presented in Chapter 6). Section 2.13 presents a simple 
and rapid protocol for researchers to generate the desired stable Tet-On cell lines, 
which will serve as a very good starting point for numerous research projects. The 
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entire protocol (preparation of constructs, generation of stable cell lines and 
functional analysis) can be completed in 3 months.  
Although Srxn1 was successfully demonstrated to be protective against 
rotenone treatment (Chapter 6), there are still a few unanswered questions that can be 
addressed in the future studies: 
1. What are the biological processes involved in the protective action of Srxn1? 
Srxn1 and its connection to ALP inhibition as hypothesized in Figure 6.8 can be 
studied by transcriptome analysis performed on Dox-induced differentiated SH-
SY5Y Flag-Srxn1 treated with rotenone. 
2. Can the addition of purified Srxn1 recombinant protein to the culture medium 
rescue neurons from rotenone-mediated injury? If so, what is the transport 
mechanism located on the plasma membrane allowing the entry of extracellular 
Srxn1? 
3. Based on this current study, neurite degeneration caused by rotenone appears 
before the over-expression of Srxn1. However, further investigation is needed to 
confirm if Srxn1 is required before or after the onset of the cell death mechanism. 
The knowledge of the time frame for Srxn1 to work effectively is critical as most 
of the neurological diseases are unable to be diagnosed at an early stage.  
4. What are the Srxn1 interacting partners during rotenone-induced neuronal injury? 
Following the identification of interacting partners, drugs can be designed to 
enhance or inhibit the interaction which might revert the progression of 
neurodegeneration. 
In closing, the significance of Srxn1 overexpression discussed above is speculative, 
and attempts to provide interesting clues for the potential role of Srxn1 in oxidative 
stress induced neurodegeneration. These promising results will hopefully open the 
door for the development of agents that increase Srxn1 expression or enhance its 
activity.  
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Appendix A: Selected differentially expressed gene profile of neuronal death affected 
cellular processes in cultured cortical neurons treated with 10 nM rotenone. Data are 
expressed as mean ± SE. 
Genbank Symbol Gene Name 8 h 15 h 24 h 
Mitochondrial dysfunction ▲15 ▼17 
▲ 4 
▼ 28 
▲ 4 
▼ 28 
Mitochondria Inner membrane 
NM_025313 Atp5d 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, 
delta subunit  
-1.16 ± 0.03 -1.77 ± 0.23 -1.66 ± 0.06 
NM_138597 Atp5o 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, O 
subunit  
-1.23 ± 0.15 -1.56 ± 0.15 -1.84 ± 0.05 
NM_009943 Cox6a2 cytochrome c oxidase, subunit VI a, polypeptide 2  1.25 ± 0.06 -1.87 ± 0.04 -1.13 ± 0.05 
NM_007751 Cox8b cytochrome c oxidase, subunit VIIIb  -1.26 ± 0.07 2.89 ± 0.59 1.55 ± 0.17 
NM_007806 Cyba cytochrome b-245, alpha polypeptide  -1.38 ± 0.12 2.18 ± 0.43 2.82 ± 0.51 
NM_025567 Cyc1 cytochrome c-1  -1.06 ± 0.09 -1.55 ± 0.23 -1.40 ± 0.06 
NM_007808 Cycs cytochrome c, somatic  1.13 ± 0.05 -1.59 ± 0.10 -1.36 ± 0.08 
NM_026614 Ndufa5 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 5  
-1.21 ± 0.14 -1.71 ± 0.21 -1.80 ± 0.01 
NM_026703 Ndufa8 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 8  
-1.18 ± 0.17 -1.47 ± 0.11 -1.69 ± 0.08 
NM_025358 Ndufa9 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 9  
-1.23 ± 0.12 -1.52 ± 0.18 -1.96 ± 0.05 
NM_026061 Ndufb8 
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 
8  
-1.22 ± 0.14 -1.44 ± 0.11 -2.01 ± 0.07 
NM_153064 Ndufs2 NADH dehydrogenase (ubiquinone) Fe-S protein 2  -1.16 ± 0.14 -1.23 ± 0.29 -1.74 ± 0.04 
XM_130347 Ndufs3 NADH dehydrogenase (ubiquinone) Fe-S protein 3  -1.29 ± 0.10 -1.50 ± 0.16 -1.77 ± 0.08 
NM_010887 Ndufs4 NADH dehydrogenase (ubiquinone) Fe-S protein 4  -1.18 ± 0.12 -1.54 ± 0.09 -2.01 ± 0.03 
NM_011671 Ucp2 uncoupling protein 2, mitochondrial  -1.03 ± 0.06 1.14 ± 0.06 1.64 ± 0.14 
NM_025407 Uqcrc1 ubiquinol-cytochrome c reductase core protein 1  -1.17 ± 0.03 -2.06 ± 0.24 -1.71 ± 0.06 
NM_025899 Uqcrc2 ubiquinol cytochrome c reductase core protein 2  1.17 ± 0.09 -1.32 ± 0.14 -1.50 ± 0.06 
mitochondrial outer membrane 
NM_023732 Abcb6 
ATP-binding cassette, sub-
family B (MDR/TAP), member 
6 
1.15 ± 0.15 -1.66 ± 0.10 -1.56 ± 0.04 
NM_009648 Akap1 A kinase (PRKA) anchor protein 1 1.26 ± 0.22 -1.95 ± 0.17 -2.44 ± 0.02 
NM_007522 Bad BCL2-associated agonist of cell death -1.06 ± 0.06 -2.09 ± 0.12 -2.01 ± 0.07 
NM_009743 Bcl2l1 BCL2-like 1 1.27 ± 0.24 -1.68 ± 0.03 -1.22 ± 0.12 
NM_007537 Bcl2l2 BCL2-like 2 -1.01 ± 0.05 -1.81 ± 0.15 -1.51 ± 0.04 
NM_152816 Dnm1l dynamin 1-like 1.07 ± 0.14 -1.54 ± 0.16 -1.83 ± 0.05 
NM_025562 Fis1 fission 1 (mitochondrial outer membrane) homolog (yeast) 1.02 ± 0.03 -1.67 ± 0.35 -1.41 ± 0.08 
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NM_019694 Letm1 
leucine zipper-EF-hand 
containing transmembrane 
protein 1 
1.14 ± 0.16 -1.75 ± 0.22 -2.14 ± 0.05 
NM_024200 Mfn1 mitofusin 1 1.08 ± 0.25 1.52 ± 0.14 1.25 ± 0.13 
NM_133201 Mfn2 mitofusin 2  1.02 ± 0.02 -1.67 ± 0.04 -1.97 ± 0.05 
NM_028392 Ppp2r2b 
protein phosphatase 2 (formerly 
2A), regulatory subunit B (PR 
52), beta isoform 
-1.01 ± 0.06 -2.77 ± 0.05 -3.31 ± 0.02 
NM_025996 Tomm34 translocase of outer mitochondrial membrane 34 1.14 ± 0.23 -1.70 ± 0.17 -1.65 ± 0.03 
NM_025365 Tomm6 
translocase of outer 
mitochondrial membrane 6 
homolog (yeast) 
1.18 ± 0.07 -2.21 ± 0.05 -1.47 ± 0.04 
NM_138599 Tomm70a 
translocase of outer 
mitochondrial membrane 70 
homolog A (yeast) 
1.03 ± 0.10 -1.77 ± 0.06 -1.72 ± 0.05 
NM_031877 Wasf1 WASP family 1 1.11 ± 0.05 -2.39 ± 0.03 -3.75 ± 0.02 
Apoptogenic signalling ▲ 8 ▼ 10 
▲ 17 
▼ 1 
▲ 16 
▼ 2 
NM_018830 Asah2 N-acylsphingosine amidohydrolase 2 -1.09 ± 0.05 1.33 ± 0.11 1.75 ± 0.03 
NM_177410 Bcl2 B-cell leukemia/lymphoma 2 1.18 ± 0.39 1.42 ± 0.11 2.31 ± 0.08 
NM_007610 Casp2 caspase 2  -1.07 ± 0.12 -1.05 ± 0.23 -1.74 ± 0.03 
NM_009812 Casp8 caspase 8 -1.02 ± 0.08 1.27 ± 0.14 1.58 ± 0.09 
NM_008364 Il1rap interleukin 1 receptor accessory protein 1.03 ± 0.04 1.74 ± 0.13 1.34 ± 0.03 
NM_017372 Lyzs lysozyme 2 -1.00 ± 0.05 1.55 ± 0.13 2.16 ± 0.18 
NM_026012 Nradd neurotrophin receptor associated death domain 1.17 ± 0.07 1.25 ± 0.20 1.64 ± 0.14 
NM_008654 Ppp1r15a 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
15A 
1.63 ± 0.39 2.11 ± 0.98 6.40 ± 0.60 
NM_009163 Sgpl1 sphingosine phosphate lyase 1 -1.08 ± 0.04 1.57 ± 0.24 1.78 ± 0.07 
NM_009289 Slk STE20-like kinase (yeast) 1.07 ± 0.11 1.40 ± 0.13 1.66 ± 0.12 
NM_009367 Tgfb2 transforming growth factor, beta 2 1.25 ± 0.27 1.75 ± 0.23 1.69 ± 0.10 
NM_020275 Tnfrsf10b tumor necrosis factor receptor superfamily, member 10b -1.01 ± 0.08 1.52 ± 0.09 2.16 ± 0.19 
NM_013749 Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 1.84 ± 1.29 4.13 ± 1.67 21.86 ± 1.06 
NM_013869 Tnfrsf19 tumor necrosis factor receptor superfamily, member 19 1.12 ± 0.11 1.86 ± 0.25 1.25 ± 0.09 
NM_011609 Tnfrsf1a tumor necrosis factor receptor superfamily, member 1a -1.17 ± 0.09 1.28 ± 0.57 2.79 ± 0.26 
NM_007987 Tnfrsf6 Fas (TNF receptor superfamily member 6) -1.00 ± 0.18 1.71 ± 0.14 2.46 ± 0.16 
NM_009421 Traf1 TNF receptor-associated factor 1 -1.35 ± 0.09 1.62 ± 0.10 1.56 ± 0.09 
NM_009423 Traf4 TNF receptor associated factor 4 -1.15 ± 0.10 1.63 ± 0.36 -1.78 ± 0.08 
Calcium signaling ▲ 10 ▼ 8 
▲ 8 
▼ 10 
▲ 8 
▼ 10 
NM_007585 Anxa2 annexin A2  -1.07 ± 0.24 2.05 ± 0.62 2.76 ± 0.32 
NM_013470 Anxa3 annexin A3  -1.22 ± 0.25 4.15 ± 0.81 20.05 ± 2.21 
NM_009673 Anxa5 annexin A5  -1.09 ± 0.21 1.82 ± 0.46 3.23 ± 0.22 
NM_009723 Atp2b2 ATPase, Ca++ transporting, plasma membrane 2 1.16 ± 0.21 -1.83 ± 0.09 
 
-2.13 ± 0.02 
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Genbank Symbol Gene Name 8 h 15 h 24 h 
NM_007586 Calb2 calbindin 2  1.25 ± 0.03 -3.34 ± 0.07 -4.44 ± 0.01 
NM_177343 Camk1d calcium/calmodulin-dependent protein kinase ID -1.02 ± 0.13 -1.93 ± 0.08 -1.87 ± 0.02 
NM_144817 Camk1g calcium/calmodulin-dependent protein kinase I gamma 1.03 ± 0.05 -2.30 ± 0.05 -2.56 ± 0.03 
NM_177407 Camk2a calcium/calmodulin-dependent protein kinase II alpha 1.09 ± 0.09 -2.57 ± 0.09 -2.89 ± 0.03 
NM_007595 Camk2b calcium/calmodulin-dependent protein kinase II, beta 1.23 ± 0.02 -5.23 ± 0.07 -3.91 ± 0.02 
NM_178597 Camk2g calcium/calmodulin-dependent protein kinase II gamma 1.03 ± 0.12 -2.20 ± 0.14 -2.25 ± 0.02 
NM_018883 Camkk1 calcium/calmodulin-dependent protein kinase kinase 1, alpha 1.19 ± 0.15 -2.36 ± 0.06 -2.47 ± 0.03 
NM_145358 Camkk2 calcium/calmodulin-dependent protein kinase kinase 2, beta 1.38 ± 0.23 -3.27 ± 0.10 -2.40 ± 0.02 
NM_012040 Pnck 
pregnancy upregulated non-
ubiquitously expressed CaM 
kinase 
1.14 ± 0.28 -2.66 ± 0.10 -2.48 ± 0.01 
NM_011309 S100a1 S100 calcium binding protein A1 -1.23 ± 0.08 1.17 ± 0.47 1.55 ± 0.17 
NM_016740 S100a11 S100 calcium binding protein A11 (calizzarin)  1.04 ± 0.15 1.60 ± 0.15 3.66 ± 0.38 
NM_009113 S100a13 S100 calcium binding protein A13  -1.28 ± 0.08 1.23 ± 0.23 1.28 ± 0.06 
NM_011311 S100a4 S100 calcium binding protein A4 -1.16 ± 0.16 1.55 ± 0.08 1.53 ± 0.18 
NM_011313 S100a6 S100 calcium binding protein A6 (calcyclin)  -1.34 ± 0.17 1.88 ± 0.21 1.95 ± 0.12 
Ubiquitin proteasome system ▲ 17 ▼ 15 
▲ 0 
▼ 32 
▲ 0 
▼ 32 
NM_009771 Btrc beta-transducin repeat containing protein -1.05 ± 0.14 -1.89 ± 0.13 -1.78 ± 0.03 
NM_080428 Fbxw7 F-box and WD-40 domain protein 7 1.10 ± 0.05 -3.34 ± 0.04 -4.00 ± 0.03 
NM_011965 Psma1 
proteasome (prosome, 
macropain) subunit, alpha type 
1 
-1.25 ± 0.29 -1.44 ± 0.20 -1.86 ± 0.05 
NM_011969 Psma7 
proteasome (prosome, 
macropain) subunit, alpha type 
7 
-1.00 ± 0.11 -1.35 ± 0.13 -1.59 ± 0.04 
NM_011185 Psmb1 proteasome (prosome, macropain) subunit, beta type 1 -1.10 ± 0.14 -1.52 ± 0.09 -1.86 ± 0.02 
NM_011970 Psmb2 proteasome (prosome, macropain) subunit, beta type 2 1.07 ± 0.03 -1.44 ± 0.09 -1.70 ± 0.06 
NM_011186 Psmb5 proteasome (prosome, macropain) subunit, beta type 5 1.09 ± 0.16 -1.60 ± 0.12 -1.33 ± 0.09 
NM_008946 Psmb6 proteasome (prosome, macropain) subunit, beta type 6 -1.00 ± 0.10 -1.44 ± 0.10 -1.61 ± 0.08 
NM_009439 Psmd3 
proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 3 
1.08 ± 0.02 -1.59 ± 0.10 -1.42 ± 0.02 
NM_010817 Psmd7 
proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 7 
1.06 ± 0.32 -1.23 ± 0.13 -1.50 ± 0.05 
NM_026545 Psmd8 
proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 8 
-1.05 ± 0.01 -1.59 ± 0.12 -1.38 ± 0.07 
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Genbank Symbol Gene Name 8 h 15 h 24 h 
NM_011190 Psme2 protease (prosome, macropain) 28 subunit beta B, pseudogene -1.36 ± 0.24 -1.53 ± 0.03 -1.87 ± 0.07 
NM_009460 Sumo1 SMT3 suppressor of mif two 3 homolog 1 (yeast) -1.12 ± 0.17 -1.77 ± 0.17 -1.95 ± 0.05 
NM_028769 Syvn1 synovial apoptosis inhibitor 1, synoviolin 1.01 ± 0.07 -1.86 ± 0.05 -2.10 ± 0.04 
NM_053084 Trim32 tripartite motif-containing 32 -1.00 ± 0.13 -1.82 ± 0.04 -1.82 ± 0.01 
NM_009457 Ube1x ubiquitin-like modifier activating enzyme 1 1.18 ± 0.07 -2.93 ± 0.17 -2.85 ± 0.02 
NM_019912 Ube2d2 ubiquitin-conjugating enzyme E2D 2 1.02 ± 0.08 -1.99 ± 0.04 -2.42 ± 0.03 
NM_025356 Ube2d3 
ubiquitin-conjugating enzyme 
E2D 3 (UBC4/5 homolog, 
yeast) 
-1.20 ± 0.19 -2.23 ± 0.01 -2.82 ± 0.05 
NM_144839 Ube2e2 
ubiquitin-conjugating enzyme 
E2E 2 (UBC4/5 homolog, 
yeast) 
1.06 ± 0.06 -1.49 ± 0.15 -1.74 ± 0.07 
NM_025985 Ube2g1 
ubiquitin-conjugating enzyme 
E2G 1 (UBC7 homolog, C. 
elegans) 
1.13 ± 0.05 -2.02 ± 0.03 -1.85 ± 0.03 
NM_145578 Ube2m ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast) 1.17 ± 0.11 -2.65 ± 0.17 -1.96 ± 0.09 
NM_080560 Ube2n ubiquitin-conjugating enzyme E2N -1.02 ± 0.17 -3.78 ± 0.05 -4.03 ± 0.01 
NM_027315 Ube2q1 ubiquitin-conjugating enzyme E2Q (putative) 1 1.19 ± 0.05 -1.99 ± 0.04 -1.90 ± 0.06 
NM_180600 Ube2q2 ubiquitin-conjugating enzyme E2Q (putative) 2 1.03 ± 0.11 -1.17 ± 0.04 -1.51 ± 0.06 
NM_023230 Ube2v1 ubiquitin-conjugating enzyme E2 variant 1 1.06 ± 0.27 -2.42 ± 0.09 -1.99 ± 0.08 
NM_172300 Ube2z ubiquitin-conjugating enzyme E2Z (putative) -1.10 ± 0.24 -2.09 ± 0.17 -2.14 ± 0.04 
NM_054093 Ube3b ubiquitin protein ligase E3B -1.12 ± 0.04 -2.78 ± 0.13 -2.17 ± 0.05 
NM_133907 Ube3c ubiquitin protein ligase E3C -1.01 ± 0.16 -2.36 ± 0.11 -2.31 ± 0.05 
NM_011670 Uchl1 ubiquitin carboxy-terminal hydrolase L1 1.09 ± 0.12 -4.32 ± 0.12 -3.42 ± 0.01 
NM_011669 Usp12 ubiquitin specific peptidase 12 -1.11 ± 0.13 -1.84 ± 0.13 -2.34 ± 0.01 
NM_013919 Usp21 ubiquitin specific peptidase 21 1.01 ± 0.08 -1.81 ± 0.16 -1.77 ± 0.04 
NM_199143 Znrf2 zinc and ring finger 2 1.06 ± 0.25 -3.29 ± 0.01 -3.00 ± 0.04 
Chaperones/co-chaperones ▲ 15 ▼ 6 
▲ 4 
▼ 17 
▲ 4 
▼ 17 
NM_013559 Hsp105 heat shock 105kDa/110kDa protein 1 1.14 ± 0.10 -2.27 ± 0.10 -2.11 ± 0.06 
NM_031165 Hspa8 heat shock protein 8  -1.07 ± 0.14 -2.57 ± 0.04 -1.93 ± 0.13 
NM_010481 Hspa9 heat shock protein 9 1.09 ± 0.08 2.14 ± 0.61 2.67 ± 0.28 
NM_013560 Hspb1 heat shock protein 1  1.02 ± 0.14 1.36 ± 0.11 3.86 ± 0.17 
NM_019960 Hspb3 heat shock protein 3  1.20 ± 0.11 -1.40 ± 0.05 -1.33 ± 0.10 
NM_030704 Hspb8 heat shock protein 8  -1.02 ± 0.24 5.08 ± 0.31 8.27 ± 0.58 
NM_008302 Hsp90ab1 heat shock protein 90 alpha (cytosolic), class B member 1 1.07 ± 0.09 -1.76 ± 0.25 -1.63 ± 0.02 
NM_013863 Bag3 Bcl2-associated athanogene 3  -1.09 ± 0.38 1.80 ± 0.44 2.39 ± 0.11 
NM_027404 Bag5 BCL2-associated athanogene 5  1.04 ± 0.05 -1.49 ± 0.19 -1.54 ± 0.05 
NM_019794 Dnaja2 DnaJ (Hsp40) homolog, subfamily A, member 2 -1.01 ± 0.15 -1.69 ± 0.11 -1.94 ± 0.04 
NM_019874 Dnajb5 DnaJ (Hsp40) homolog, subfamily B, member 5 1.20 ± 0.08 -2.54 ± 0.04 -2.31 ± 0.03 
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Genbank Symbol Gene Name 8 h 15 h 24 h 
NM_139139 Dnajc17 DnaJ (Hsp40) homolog, subfamily C, member 17 1.03 ± 0.06 -1.69 ± 0.20 -1.61 ± 0.04 
NM_025362 Wbscr18 DnaJ (Hsp40) homolog, subfamily C, member 30 1.06 ± 0.08 -1.92 ± 0.09 -1.85 ± 0.04 
NM_016775 Dnajc5 DnaJ (Hsp40) homolog, subfamily C, member 5 1.09 ± 0.08 -2.34 ± 0.16 -2.86 ± 0.01 
NM_198412 Dnajc6 DnaJ (Hsp40) homolog, subfamily C, member 6 -1.32 ± 0.14 -6.14 ± 0.09 -8.05 ± 0.01 
NM_019795 Dnajc7 DnaJ (Hsp40) homolog, subfamily C, member 7 1.07 ± 0.07 -1.82 ± 0.05 -2.03 ± 0.01 
NM_008019 Fkbp1a FK506 binding protein 1a 1.11 ± 0.15 -2.06 ± 0.25 -1.76 ± 0.09 
NM_016863 Fkbp1b FK506 binding protein 1b -1.05 ± 0.08 -3.32 ± 0.04 -3.25 ± 0.02 
NM_010219 Fkbp4 FK506 binding protein 4 1.13 ± 0.05 -2.44 ± 0.15 -2.06 ± 0.04 
NM_010220 Fkbp5 FK506 binding protein 5 1.04 ± 0.08 -1.80 ± 0.04 -1.64 ± 0.03 
NM_010223 Fkbp8 FK506 binding protein 8 1.04 ± 0.04 -2.18 ± 0.14 -1.70 ± 0.04 
Unfolded protein response ▲ 12 ▼ 8 
▲ 6 
▼ 14 
▲ 6 
▼ 14 
NM_007837 Ddit3 DNA-damage inducible transcript 3 1.26 ± 0.47 4.60 ± 2.01 7.36 ± 0.89 
NM_019827 Gsk3b glycogen synthase kinase 3 beta 1.37 ± 0.41 -1.53 ± 0.20 -2.15 ± 0.05 
NM_008654 Myd116 myeloid differentiation primary response gene 116 1.63 ± 0.39 2.11 ± 0.98 6.40 ± 0.60 
NM_133819 Ppp1r15b 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
15b 
1.19 ± 0.01 1.78 ± 0.24 1.76 ± 0.03 
NM_153178 Eif2c2 eukaryotic translation initiation factor 2C, 2  1.19 ± 0.36 -1.20 ± 0.32 -1.62 ± 0.05 
NM_145371 Eif2b1 eukaryotic translation initiation factor 2B, subunit 1 (alpha)  -1.01 ± 0.08 -1.47 ± 0.24 -1.62 ± 0.11 
NM_145445 Eif2b2 eukaryotic translation initiation factor 2B, subunit 2 beta  1.04 ± 0.12 -1.60 ± 0.15 -1.57 ± 0.05 
NM_010122 Eif2b4 eukaryotic translation initiation factor 2B, subunit 4 delta  1.05 ± 0.04 -1.81 ± 0.13 -1.78 ± 0.05 
NM_172265 Eif2b5 eukaryotic translation initiation factor 2B, subunit 5 epsilon  1.09 ± 0.01 -2.25 ± 0.15 -1.97 ± 0.03 
NM_031868 Ppp1ca protein phosphatase 1, catalytic subunit, alpha isoform  -1.21 ± 0.29 -2.02 ± 0.32 -2.04 ± 0.07 
NM_181595 Ppp1r9a 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
9A  
-1.14 ± 0.06 -2.72 ± 0.06 -3.87 ± 0.02 
NM_016854 Ppp1r3c 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
3C  
-1.11 ± 0.17 -1.26 ± 0.12 -2.03 ± 0.05 
NM_012016 Ern2 endoplasmic reticulum (ER) to nucleus signalling 2 -1.00 ± 0.10 1.82 ± 0.34 3.65 ± 0.80 
NM_009716 Atf4 activating transcription factor 4  1.40 ± 0.19 2.36 ± 0.16 2.41 ± 0.52 
NM_009883 Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1.40 ± 0.54 2.27 ± 0.51 4.52 ± 0.12 
NM_013842 Xbp1 X-box binding protein 1 -1.10 ± 0.24 -2.50 ± 0.08 -2.96 ± 0.01 
NM_145537 Edem2 ER degradation enhancer, mannosidase alpha-like 2 1.19 ± 0.12 -1.30 ± 0.07 -1.67 ± 0.03 
NM_011643 Trpc1 
transient receptor potential 
cation channel, subfamily C, 
member 1  
-1.03 ± 0.22 -1.59 ± 0.07 -1.54 ± 0.05 
NM_009287 Stim1 stromal interaction molecule 1  1.08 ± 0.18 -1.62 ± 0.20 -1.92 ± 0.05 
NM_019709 Mbtps1 membrane-bound transcription factor protease, site 1  -1.05 ± 0.08 -1.35 ± 0.18 -1.65 ± 0.02 
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Genbank Symbol Gene Name 8 h 15 h 24 h 
Autophagy-lysosomal pathway ▲ 19 ▼ 14 
▲ 20 
▼ 13 
▲ 20 
▼ 13 
NM_007644 Scarb2 scavenger receptor class B, member 2 -1.07 ± 0.08 2.24 ± 0.62 1.26 ± 0.13 
NM_007653 Cd63 CD63 antigen -1.16 ± 0.11 3.22 ± 0.52 3.42 ± 0.31 
NM_007798 Ctsb cathepsin B 1.01 ± 0.06 1.42 ± 0.08 1.95 ± 0.18 
NM_009853 Cd68 CD68 antigen -1.12 ± 0.13 1.46 ± 0.15 6.43 ± 0.95 
NM_009982 Ctsc cathepsin C 1.19 ± 0.14 2.27 ± 0.34 3.44 ± 0.33 
NM_009983 Ctsd cathepsin D -1.20 ± 0.07 1.18 ± 0.38 1.85 ± 0.08 
NM_010215 Il4i1 interleukin 4 induced 1 1.08 ± 0.17 1.20 ± 0.14 1.74 ± 0.17 
NM_010685 Lamp2 lysosomal-associated membrane protein 2 1.01 ± 0.09 2.53 ± 0.30 2.57 ± 0.21 
NM_010686 Laptm5 lysosomal-associated protein transmembrane 5 -1.05 ± 0.07 1.99 ± 0.55 2.79 ± 0.17 
NM_011175 Lgmn legumain -1.16 ± 0.11 -1.48 ± 0.19 -1.64 ± 0.06 
NM_013602 Mt1 metallothionein 1 -1.21 ± 0.08 2.01 ± 0.07 1.97 ± 0.11 
NM_016898 Cd164 CD164 antigen -1.13 ± 0.10 2.38 ± 0.41 2.26 ± 0.19 
NM_019406 Fnbp1 formin binding protein 1 1.16 ± 0.16 1.59 ± 0.07 2.02 ± 0.09 
NM_019734 Asah1 N-acylsphingosine amidohydrolase 1 1.11 ± 0.11 2.76 ± 1.18 2.83 ± 0.40 
NM_022325 Ctsz cathepsin Z -1.18 ± 0.13 1.55 ± 0.42 2.16 ± 0.15 
NM_023409 Npc2 Niemann Pick type C2 1.02 ± 0.19 1.82 ± 0.14 1.77 ± 0.22 
NM_031843 Dpp7 dipeptidylpeptidase 7 1.04 ± 0.24 1.93 ± 0.76 1.42 ± 0.15 
NM_033521 Laptm4b lysosomal-associated protein transmembrane 4B -1.19 ± 0.08 1.68 ± 0.20 1.56 ± 0.26 
NM_013603 Mt3 metallothionein 3  -1.13 ± 0.28 1.05 ± 0.21 1.96 ± 0.35 
NM_008630 Mt2 metallothionein 2  -1.15 ± 0.09 2.41 ± 0.22 2.48 ± 0.24 
NM_174874 Atg4b autophagy-related 4B (yeast) 1.07 ± 0.08 -1.93 ± 0.08 -2.36 ± 0.03 
NM_025770 Atg10 autophagy 10-like (S. cerevisiae) 1.00 ± 0.09 -1.25 ± 0.12 -1.52 ± 0.06 
NM_029846 Atg16l1 autophagy-related 16-like 1 (yeast) 1.19 ± 0.24 -2.22 ± 0.12 -2.04 ± 0.04 
NM_172669 Ambra1 autophagy/beclin 1 regulator 1 1.05 ± 0.22 -1.65 ± 0.11 -1.78 ± 0.03 
NM_019584 Becn1 beclin 1 (coiled-coil, myosin-like BCL2-interacting protein)  1.03 ± 0.08 -1.53 ± 0.17 -1.44 ± 0.04 
NM_029653 Dapk1 death associated protein kinase 1  1.06 ± 0.05 -1.65 ± 0.02 -2.17 ± 0.06 
NM_007765 Crmp1 collapsin response mediator protein 1  1.43 ± 0.22 -5.24 ± 0.04 -4.09 ± 0.03 
NM_020590 Gabarapl1 
gamma-aminobutyric acid 
(GABA(A)) receptor-associated 
protein-like 1 
1.01 ± 0.03 -1.36 ± 0.15 -1.55 ± 0.08 
NM_025735 Map1lc3a microtubule-associated protein 1 light chain 3 alpha  -1.01 ± 0.05 -3.59 ± 0.20 -2.89 ± 0.04 
NM_026160 Map1lc3b microtubule-associated protein 1 light chain 3 beta 1.01 ± 0.03 -1.41 ± 0.20 -1.79 ± 0.04 
NM_145570 Fam176a family with sequence similarity 176, member A -1.04 ± 0.38 2.68 ± 0.53 2.68 ± 0.14 
NM_009000 Rab24 RAB24, member RAS oncogene family 1.04 ± 0.06 -1.60 ± 0.10 -1.68 ± 0.07 
NM_020009 Mtor mammalian target of rapamycin (serine/threonine kinase) 1.06 ± 0.18 -2.06 ± 0.06 -2.02 ± 0.05 
Glutathione metabolism ▲ 2 ▼ 15 
▲ 14 
▼ 3 
▲ 14 
▼ 3 
NM_022992 Arl6ip5 ADP-ribosylation factor-like 6 interacting protein 5 -1.00 ± 0.09 -1.95 ± 0.15 -2.13 ± 0.04 
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NM_008129 Gclm glutamate-cysteine ligase, modifier subunit -1.23 ± 0.08 3.39 ± 0.45 5.36 ± 0.17 
NM_026637 Ggct gamma-glutamyl cyclotransferase -1.16 ± 0.19 -3.95 ± 0.05 -4.87 ± 0.01 
NM_010344 Gsr glutathione reductase -1.25 ± 0.08 1.89 ± 0.22 1.78 ± 0.17 
NM_008180 Gss glutathione synthetase 1.01 ± 0.06 1.50 ± 0.33 2.33 ± 0.17 
NM_008181 Gsta1 glutathione S-transferase, alpha 1 (Ya) 1.07 ± 0.07 3.05 ± 0.45 10.66 ± 1.12 
NM_008182 Gsta2 glutathione S-transferase, alpha 2 (Yc2) -1.17 ± 0.07 4.97 ± 0.52 18.27 ± 0.75 
NM_010356 Gsta3 glutathione S-transferase, alpha 3 -1.18 ± 0.19 2.16 ± 0.16 5.06 ± 0.97 
NM_010357 Gsta4 glutathione S-transferase, alpha 4 -1.91 ± 0.03 2.91 ± 0.32 5.77 ± 0.15 
NM_010358 Gstm1 glutathione S-transferase, mu 1 -1.43 ± 0.16 1.56 ± 0.20 1.88 ± 0.15 
NM_008183 Gstm2 glutathione S-transferase, mu 2 -1.12 ± 0.11 1.59 ± 0.03 2.42 ± 0.25 
NM_008184 Gstm6 glutathione S-transferase, mu 6 -1.42 ± 0.15 1.31 ± 0.39 2.18 ± 0.45 
NM_019946 Mgst1 microsomal glutathione S-transferase 1 -1.40 ± 0.20 2.56 ± 0.35 2.12 ± 0.16 
NM_009199 Slc1a1 
solute carrier family 1 
(neuronal/epithelial high 
affinity glutamate transporter, 
system Xag), member 1 
-1.16 ± 0.09 -6.48 ± 0.06 -12.12 ± 0.01 
NM_145079 Ugt1a6a UDP glucuronosyltransferase 1 family, polypeptide A6A -1.43 ± 0.14 2.11 ± 0.13 3.49 ± 0.38 
NM_201410 Ugt1a6b UDP glucuronosyltransferase 1 family, polypeptide A6B -1.53 ± 0.11 2.41 ± 0.54 3.18 ± 0.16 
NM_201642 Ugt1a7c UDP glucuronosyltransferase 1 family, polypeptide A7C -1.53 ± 0.11 2.40 ± 0.57 3.37 ± 0.52 
Endogenous defense against oxidative stress via Nrf2 
pathway 
▲ 7 
▼ 10 
▲ 16 
▼ 1 
▲ 16 
▼ 1 
NM_007498 Atf3 activating transcription factor 3 1.52 ± 0.84 3.63 ± 0.87 9.65 ± 0.75 
NM_009716 Atf4 activating transcription factor 4 1.40 ± 0.19 2.36 ± 0.16 2.41 ± 0.52 
NM_030693 Atf5 activating transcription factor 5 1.32 ± 0.15 1.80 ± 0.78 2.59 ± 0.26 
NM_009883 Cebpb CCAAT/enhancer binding protein (C/EBP), beta  1.40 ± 0.54 2.27 ± 0.51 4.52 ± 0.12 
NM_008129 Gclm glutamate-cysteine ligase, modifier subunit -1.23 ± 0.08 3.39 ± 0.45 5.36 ± 0.17 
NM_008180 Gss glutathione synthetase 1.01 ± 0.06 1.50 ± 0.33 2.33 ± 0.17 
NM_008182 Gsta2 glutathione S-transferase, alpha 2 (Yc2) -1.17 ± 0.07 4.97 ± 0.52 18.27 ± 0.75 
NM_010442 Hmox1 heme oxygenase (decycling) 1 -1.00 ± 0.46 14.26 ± 2.29 23.87 ± 1.59 
NM_016679 Keap1 kelch-like ECH-associated protein 1 -1.06 ± 0.07 -1.58 ± 0.04 -1.85 ± 0.04 
NM_010755 Maff 
v-maf musculoaponeurotic 
fibrosarcoma oncogene family, 
protein F (avian) 
1.28 ± 0.37 1.41 ± 0.12 2.67 ± 0.29 
NM_013602 Mt1 metallothionein 1 -1.21 ± 0.08 2.01 ± 0.07 1.97 ± 0.11 
NM_008630 Mt2 metallothionein 2 -1.15 ± 0.09 2.41 ± 0.22 2.48 ± 0.24 
NM_010902 Nfe2l2 nuclear factor, erythroid derived 2, like 2 1.12 ± 0.18 3.55 ± 0.42 3.80 ± 0.53 
NM_008706 Nqo1 NAD(P)H dehydrogenase, quinone 1 -1.21 ± 0.12 1.59 ± 0.17 1.89 ± 0.10 
NM_007453 Prdx6 peroxiredoxin 6 -1.32 ± 0.12 1.43 ± 0.23 2.41 ± 0.36 
NM_029688 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) -1.23 ± 0.13 6.79 ± 1.26 9.84 ± 1.63 
NM_015762 Txnrd1 thioredoxin reductase 1 -1.01 ± 0.05 1.75 ± 0.06 3.11 ± 0.31 
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Appendix B: Selected differentially expressed gene profile of neuronal death affected cellular processes in cultured cortical neurons treated with rotenone, 
lactacystin and NMDA. Data are expressed as mean ± SE. 
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